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Abstract
Low Dose Rate brachytherapy is a widely used procedure in Australia and in the
world to cure prostate cancer. Commercial Treatment Planning System (TPS) used
in every day clinical practice approximates all tissues to water, neglecting the existence of calcifications. However, their presence in the prostate may perturb the dose
because of their higher photoelectric effect cross section in comparison to water.
This study addresses quantitatively the effect of prostatic calcification in the clinical outcome of brachytherapy treatment, through of experimental measurements and
Monte Carlo simulations.
Four pathological calcification samples were characterised with µ-PIXE to determine
their heavy elemental composition. Spectral analysis detected eight elements with
atomic number greater than 13. It was discovered that calcium, phosphorus and zinc
were the most predominant heavy elements in the calcification composition.
The dosimetric effect of the four calcification samples was studied experimentally.
Each calcification was embedded in a PMMA phantom and located between a closely
placed I-125 brachytherapy seed and a MOSkinTM detector. Dose rate reductions between 3.41% and 40.12% were observed.
Geant4 based simulations were used to evaluate quantitatively the dosimetric effect
of calcifications. Four real patient brachytherapy treatments were modelled in the
simulation experimental set-up, in terms of distribution of brachytherapy seeds and
calcifications in the prostate. Different calcification compositions were modelled.

ii

Abstract

iii

Dose reductions were observed to be around 7-20% and 20-30% for small and average sized calculi, respectively. Single large calcifications and closely placed calculi
caused dose reductions between 30-60%. It was also found that calculi smaller than
0.5mm in diameter have a negligible dosimetric impact.
The simulation study showed a varying reduction on dosimetric parameters when a
hydroxyapatite composition was adopted to model the patients’ calcifications. It was
calculated that the parameter D90 was reduced by 2-3% regardless of calcification
surface area and volume. The parameters V100 , V150 and V200 were reduced by as
much as 2.5% and on average by 1%. These reductions were also found to relate to
the surface area and volume of calcifications.
This work shows that calcifications can have a statistically significant impact on
the clinical outcome of brachytherapy treatment. Such impact depends strongly
on specific factors in the patient anatomy and treatment. These factors include the
brachytherapy seeds distribution, the number, size, composition and spatial distribution of calcifications in the prostate.
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Chapter 1
Introduction
1.1

Objectives and Overview of this Thesis

Every year, approximately 20 000 Australian men are diagnosed with prostate cancer
and of these, more than 3 000 die from the disease. This makes prostate cancer the
second highest killer in males behind lung cancer [1]. Prostate cancer occurs in men
mainly over the age of 50 and is highest in those who are 75 years or older [2]. There
is however, a small amount of men who will be diagnosed with prostate cancer at a
young age.
The prostate is a unique, ’walnut sized’ organ found only in males. The prostate is
inferior and posterior to the bladder and is anterior to the rectum. It is responsible
for the production of the white fluid found in semen [3]. The prostate also encases
the urethra which is the vital structure which allows urine and semen to pass through.
Given the position of these surrounding critical organs, it is essential to provide concise delivery of radiation to treat prostatic tumours, while sparing surround normal
tissue. The anatomy of the prostate and surrounding critical organs can be seen in
Figure 1.1.
This study will focus on the dosimetric effect of prostatic calcifications or calculi
that occur in a large population of prostate cancer patients and take specific interest
in those undergoing Low Dose Rate (LDR) Brachytherapy treatments. These cal1

Introduction

2

Figure 1.1 Anatomy of the Prostate and its Surrounding Organs [3]

cifications have shown no link to the development of prostate carcinoma thus far,
however they may be accountable for some discrepancies in the treatment for LDR
brachytherapy. In this work, the dosimetric impact of prostatic calcifications in LDR
brachytherapy was evaluated.
The major objectives of the study include determining the composition of the calcifications and their interaction with low energy radiation (less than a hundred KeV for
I-125 brachytherapy seeds) both experimentally and theoretically by means of Monte
Carlo simulations. From the study, the individual size, distribution and compositions,
which may alter the dose attenuation, will be determined for various calcification
stones/clusters around the prostate. Any differences found between individual calcification specimens obtained from pathology will also be of significant importance as
it may highlight variances that occur amongst patients with different prostate cancer
staging and grading.
Due to their relatively unknown influence, obtained results will be useful to clinicians, as they will provide sufficient evidence as to how, or if, these structures influence dose delivery and distribution.

Chapter 2
Literature Review
2.1

Prostate Cancer

Prostate cancer is the most commonly diagnosed malignancy for men in Australia
and the USA [4], with the number of new cases increasing both locally and worldwide each year. Development of this disease is relatively unknown although it has
been suggested that dietary and genetic factors may be responsible for such occurrences [5]. Other alleged risk factors include; history of benign prostatic hyperplasia,
vasectomy, sexually transmitted infectious agents, sexual activity level, androgenic
hormones, weight or obesity, cigarette smoking, alcohol and tea consumption, low
intake of Vitamin E, Vitamin D and selenium [5].
Prostate cancer severity is variable in individual men affecting each to a different
extent. It has shown to be stagnant in some cases, while others have been highly
lethal. Likewise, the genetic changes vary accordingly in individual cases. These
changes include chromosomal losses, gains and translocations [5]. It is seen that each
of these affect the individual to a different extent although similar patterns emerge
between patients.

3

Literature Review

2.1.1

4

Prostate Screening

Screening has become a useful tool in the early detection of prostate cancer, although
there has been an ongoing debate over its effectiveness due to the lack of data from
randomised clinical trials. The most effective form of screening is achieved by measuring the prostate specific antigen (PSA) level found in blood tests. The PSA is a
protein produced in the prostate gland by normal cells and usually found in its highest levels in the seminal fluid. These antigens exist in small quantities in all males
but an elevated level is often used to indicate a development of cancer and other
irregularities.
PSA testing not only helps identify men in which a prostate biopsy would be appropriate but also assists in assessing the response to therapy, determining tumour
progression, and, in its most controversial role, screening for prostate cancer [6].
Controversy surrounds prostate screening due to the over diagnosis (false positive
readings) issues that arise. There is concern that the benefit of screening may not
outweigh the risks associated with detection of latent prostate cancers that may have
no effect on survival. Over diagnosis has been calculated to be as high as 48% in
studies done over a 4 year period [7] and it has also been calculated that only 1/8th
of all screened-detected cancers will be likely to result in death if left untreated [8].
With over diagnosis, over treatment is of concern, as the complications that arise due
to radical prostatectomy and radiotherapy should be avoided if possible. Given both
the advantages and disadvantages of prostate screening most urologists believe that
there has been a reduction in the number of patients with advanced prostate cancer
since PSA testing has been utilised [6].
Ferrante et al. [9] looked at the factors that have influenced men’s choice of undergoing screening. The study looked at a group of 64 men over the age of 50, some
who had undergone screening and others who had not. The study found most men
who had previously been screened done so because of family history or as a result of
a regular physical examination. Men who had avoided screening did so for a number
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of reasons, but most felt they were at a low risk as they had a lack of family history,
they showed no sign of urinary symptoms or they were of the belief that their diet
and healthy lifestyle would been sufficient to prevent prostate cancer development.
Other reasons for avoiding screening included: fear of cancer, embarrassment over
rectal exams, scepticism and confusion of the screening process [9].

2.1.2

Histological Types of Prostate Tumours

The most common site of origin of prostate cancer is in the peripheral zone, this being
the main glandular zone of the prostate (see Figure 2.1). There are various types of
tumours found in the prostate gland although adenocarcinomas make up the majority
and account for 95% of all cases. The remaining 5% of cases consist of squamous cell
carcinoma, signet-ring carcinoma, transitional carcinoma, neuroendocrine carcinoma
or sarcoma.

Figure 2.1 Zones of the prostate devised by McNeal [10]: The peripheral zone (1), the central
zone (2), and the transition zone (3) adapted from [11].

Adenocarcinoma cancers are very diverse and can be found in various regions of the
prostate though most commonly in the peripheral zone. The tumour contains small
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glands that infiltrate larger benign glands and develop in the epithelial cells. These
cancers make up 95% of all prostate cancers.
Of all prostate cancers, squamous cell carcinoma (SCC) make up approximately 0.51% of cases. These cancers are non glandular and very aggressive in nature. It has
been found that there is no increase in PSA when SCC is present, making it hard to
detect and therefore allowing it to reach an advanced stage before noticeable changes
are seen.
Signet-Ring Carcinoma cancers are found rarely in the prostate and account for only
a minor percentage of cases. Like SCC, singlet-ring carcinoma’s have an aggressive
nature. They have been described as having an appearance similar to that of the
homonym tumour of the gastrointestinal tract [5].
Other histological types include transitional cell carcinoma (TCC), neuroendocrine
and endometriod carcinoma as well as sarcoma. These are extremely rare forms
of prostate cancer and infrequently develop in the prostate alone. Cancers of these
forms usually originate from primary tumours present in the bladder or urethra [5].

2.1.3

Grading and Staging of Prostate Cancer

The grading and staging of prostate tumours are two important factors in assessing
the severity and aggression of cancer development.
2.1.3.1

Tumour Grading

The most commonly used grading system for prostate cancer is the Gleason system [5]. This system is however, only specific to adenomcarcinoma, though as adenocarcinoma accounts for 95% of cases (as previously mentioned), it is considered
the standard for prostatic tumour grading.
The Gleason system places cancers in to 5 different grade categories. The grades
are given values 1-5 and are categorised by their glandular pattern and degree of
differentiation. The Gleason system uses two of these individual grades to provide a
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single Gleason score. The Gleason score is the sum of the most represented (primary)
grade and the second most (secondary) grade. For example a grade 4 primary cancer
and a grade 3 secondary cancer will give a Gleason score of 7 i.e. 4 + 3 = 7. The use
of 2 grade scores gives a better indication than a single Gleason grade [5] however
this system is applicable to only biopsy and surgical specimens.
2.1.3.2

Staging

There are two staging systems used for assessing prostate cancer progression, the
first is the Jewett system [5] which places cancers into stages A, B, C and D, where
• Stage A - The tumour is clinically undetectable and confined to the prostate
gland.
• Stage B - Tumour confined to the prostate gland.
• Stage C - Tumour clinically localised to the periprostatic area but extending
through the prostatic capsule; seminal vesicles may be involved.
• Stage D - Metastatic disease.
Each of these stages also contain numerous sub stages e.g. A1, A2, B0 etc which
differentiate between tumour development seen within each stage.
The second staging system is more refined and extends on the previous Jewett system; this is known as the TNM system [5]. The TNM system is more precise and
once again uses 4 main stages this time classified as stages I to IV. These stages are
essentially the same as the Jewett system although in the TNM system each of the
stages contain 3 factors, that is the primary tumour (T) the regional Lymph nodes
(N) and distant metastasis (M) [5]. These factors also contain further subcategories
as seen with the Jewett system. Staging is essential in prostate assessment as it, like
grading, can identify which treatments should be utilised to reduce spread, it can be
used in patient monitoring likewise.
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2.1.4

Diagnosis, Survival and Complications

Each year in Australia, around 3000 men die from prostate cancer; this is equal to
the number of fatalities seen in women suffering from breast cancer. This means that
for every 3 hours, 1 man will lose his battle with prostate cancer. With the number of
new cases also on the rise it is estimated that around 32 men will discover they have
the disease each day [1].
Table 2.1 Annual percentage of men who will be diagnosed with prostate cancer [1]

Age group
(years)
40-49
50-59
60-69
70-79

Chance of Diagnosis
(%)
0.1
1.2
4.5
8

Although many cases of prostate cancer arise, the chance of survival is greater than
other forms of cancer. It is also one of the only cancers that can remain in a reasonably unchanging state for many years. Depending on the development of the tumour
it is often seen that many men do not undergo treatment instantly if the severity of
their cancer is not going to cause harm in the immediate future. Mathers et al. [12]
found that localisation and tumour stage contribute greatly to a patient’s chance of
survival and long term health [12]. In the study conducted over a 10 year span using
various treatment methods, the study found that patients with stage I and II localised
prostate gland carcinoma had a 10% increase in survival in comparison to the normal
population [12].
There are many nasty side effects involved with the development of prostate cancer as
well as the complications that may arise due to treatment. These include urinary difficulties such as incontinence and erectile dysfunction, rectal bleeding and possible
sterilisation from doses to the testes. Due to the late effects of surgery and radiation
therapy, it is often beneficial to monitor tumour advancement through, what is known
as, active surveillance. Active surveillance is utilised when tumour grade is low or

Literature Review

9

patient health is not suitable for other conventional treatments. This is why patients’
current conditions are assessed thoroughly before the right treatment is selected and
applied as each individual is different. Quality of life is a major focus when prostate
cancer treatment is considered for all patients and that is why it is appropriate to treat
each individual accordingly.

2.2
2.2.1

Prostate Treatments
Ionising Radiation

Before prostate treatments can be examined in fine detail, it is essential to comprehend the way in which radiation interacts in the body, and how these interactions
influence the way treatment is accomplished. Treatment makes use of radiation that
is ionising (capable of causing damage to the DNA strand).
There are 2 general categories of ionising radiation they are directly ionising or indirectly ionising. Directly ionising radiation consists of fast electrons and heavy
charged particles. These particles deliver their energy to matter directly, through
small Coulomb-force interactions along their track [13]. Indirect ionising radiation
consists of electromagnetic radiation (gamma rays and X-rays) and neutrons. These
types of radiation do not possess charge and are incapable of causing direct ionisation; they do however transfer their energy to charged particles in the matter which
they pass through. These charged particles will then deliver the transferred energy
directly to matter as mentioned above.

2.2.2

Interaction of Photons with Matter

There are 4 possible processes a gamma or x-ray photon can undergo when interacting with matter. These are photoelectric absorption, Compton scatter, pair production
and coherent scattering.
Photoelectric absorption: photoelectric absorption occurs when an energetic photon
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interacts with an absorber atom. As the photon is absorbed by the atom, it ejects an
electron from a bound energy state (shell) known as a photoelectron. Positive ions
and characteristic X-ray emissions are also produced through photoelectric absorption. Photoelectric absorption probability cannot be expressed by a single analytic
expression however it can be approximated using the following:

Zn
τ∼
= constant 3.5
Eγ

(2.1)

[14]
Where Z = atomic number, n = 4 or 5 depending on the gamma ray energy region
of interest and Eγ is the gamma energy. From the equation it can be understood
that there is a higher probability of absorption when Z is high and/or the gamma ray
energy is low.
Compton Scatter is the interaction that takes place when incident gamma photons
interact with an electron in the absorbing medium. When concerned with gamma
energies equivalent to those of most radioisotopes, Compton scatter is often the most
dominant interaction. Compton scatter occurs when the incoming gamma is deflected
off an electron by an angle θ with respect to its original direction. In this process the
photon transfers a portion of its energy to the electron which is then recoiled and
hence given the term ’recoil electron’. The energy of the recoil electron is dependent
on the scattering angle of the incoming photon. Since all scattering angles of the
electron are possible the energy transfer can be zero to very large fractions of the
gamma-ray energy [14].
Using the conservation of momentum and energy, the energy transfer and scattering
angle can be derived to show

hν 0 =
[14]

hν
1+

hν
(1
m0 c2

− cosθ)

(2.2)
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Pair production takes place when the photon energy is in the MeV energy range. In
order for this to occur, the energy must be greater than two times the rest mass of
an electron (m0 = 0.511 MeV). If a gamma photon has energy higher than this, upon
interacting with a nucleus, its energy will be converted into mass via E = mc2 and
create an electron and positron pair. The angle of separation at which they are ejected
is dependent on the conservation of momentum.
Because of the high energies required for pair production to exist it is negligible over
the course of this study and therefore it will be neglected from further discussions.
Figure 2.2 shows the energetic probabilities for the three main interactions in an
absorbing medium.

Figure 2.2 Energetic probabilities of interaction in absorbing medium Z. Adapted from [15]

Coherent or Rayleigh scattering is another form of scattering that occurs when an
incoming gamma photon interacts coherently with electrons in the absorber atom. In
this interaction, the atom does not become excited or ionised. Instead, the photon is
scattered in a new direction without loss of energy.
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Various Prostate Treatments

There are numerous types of treatment modalities available, however selecting the
appropriate option depends on numerous factors such as initial PSA results, stage,
grade age of the patient and the treatment time required. Some strategies provide
better results if the disease is localised whilst others are more beneficial if the disease is locally advanced. Many treatments make use of ionising radiation which is
delivered to the tumour over a number of fractions (daily treatment intervals), which
may take up to several weeks in some cases.
2.2.3.1

Radical Prostatectomy

Currently one of the most common treatment options is radical prostatectomy. Radical prostatectomy requires complete removal of the prostate gland and seminal vesicles (SVs), as well as the pelvic nodes, when appropriate [16]. It’s effectiveness
lies in the ability to reduce malignant spread of the disease and its relatively short
treatment (4-5 days) and recovery period (6 weeks). The major downfalls of radical
prostatectomy include the risk of impotence and incontinence. However, over the
last 10 years, long term incontinence in patients has decreased to about 2% [1]. This
is due to the improvements in nerve sparing techniques.
2.2.3.2

EBRT, IGRT & IMRT

External beam radiation therapy (EBRT) treatments make use of medical linacs (linear accelerators) which deliver radiation through a beam of photons generated from
high energy electrons. This form of treatment is non evasive and causes the patient
little discomfort throughout treatment. Along with radical prostatectomy, EBRT is
the most sort after treatment option for prostate cancer [1].
Image guided radiotherapy (IGRT) and intensity modulated radiotherapy (IMRT) are
extensions of external beam therapy that make treatment more conformal through
the use of multiple beams and continuous radiation delivery. They provide greater
tumour volume coverage and allow more precise doses to be delivered to the prostate
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whilst sparing surrounding normal tissue [1]. Since the prostate is a mobile organ,
with motion dependent on the bowl and bladder, it is important to provide treatment
that can rectify any shifts observed through treatment. The treatment is guided by
medical images taken prior to treatment which make use of fiducial markers. Traditionally, fiducial markers are gold seeds which are inserted into the prostate to
identify the target volume position and orientation, before and during treatment of
IGRT and IMRT [1].
The advantage of IMRT and IGRT is that their implementation is not restricted by
age, they have very low complication risks and they have provided cure rates equivalent to those of surgery and brachytherapy [1]. The disadvantage of external beam
treatment is that bowel function and bother is consistently worse than those patients
undergoing surgery [17].
2.2.3.3

Hormone Therapy

Hormone therapy is the primary form of treatment when the spread of cancer has
reached an advanced stage i.e. within the bones and other additional organs [1]. Hormone therapy is used to shrink the prostate before or after treatment by suppressing
the production of testosterone. Testosterone is known to be a stimulant for cancer
growth and spread. Although hormone therapy is a simple treatment option it has
many harsh side effects, which include: hot flushes, loss of libido and erections,
sweating, mood swings, disturbed sleep, loss of energy and personal motivation,
body hair loss, bone loss, weight gain and breast development or tenderness [1]. Another downside with hormone therapy is that advanced cancers becomes resistant to
this treatment over time [1].
2.2.3.4

High Intensity Focused Ultrasound

High intensity focused ultrasound (HIFU) is a relatively recent form of therapy that
makes use of intense heat to treat prostate cancer. This heat source is delivered
through the rectum and aims to treat the prostatic gland in its totality [1]. It becomes
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an option when a patient refuses, or is not suitable for, surgery or radiotherapy. This
is usually common in older patients. It is particularly useful if other conventional
radiotherapy treatments have failed. Like most treatments, the side effects can be
painful, such as burning, difficulty in passing urine, infection and temporary incontinence [1]. These symptoms usually pass 3 months after treatment.
2.2.3.5

Focal Laser Ablation

Focal laser ablation (FLA) is being developed as a minimally invasive technique
for the treatment of low grade and localised prostate cancer. The operation of FLA is
based on the use of low powered lasers which delivers luminous energy to the tumour
through an adapted optical system.
The technical feasibility of FLA was proven after a phase 1 clinical trial was conducted on 12 patients in a Toronto facility [18]. Biopsies taken 6 months after treatment found that 67% of patients were successfully alleviated of their condition. The
biological effects of laser energy depend on the laser wavelength, laser power, the
pulse duration, blood perfusion and both the optical and thermal properties of the
tissue involved [18].
2.2.3.6

Brachytherapy

Brachytherapy treatments use internal radiation sources to treat the tumour from
within. The term brachy is derived from the Greek word meaning ’short distance’.
In brachytherapy, small radioactive sources (metallic cylinders containing an internal
radioactive source/radionuclide), as seen in Figure 2.3, are inserted or implanted into
the prostate gland through the region between the scrotum and the rectum, using
a series of thin long needles or hollow plastic catheters. The radioactive seeds are
then left to irradiate the tumour volume from within. The period over which these
seeds remain inside the prostate depend on the type of brachytherapy treatment being
employed.
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Figure 2.3 Single LDR Seed [19]

The two most prevalent types of brachytherapy options available for prostate cancer
include high dose rate brachytherapy (HDR) and low dose rate brachytherapy (LDR).
HDR Brachytherapy utilises high radiation dose rates, which can be up to 5 Gy/min
in some cases [15]. These treatments are typically employed along with external
beam therapy. HDR brachytherapy is administered through either plastic or metal
catheters inserted into the prostate gland with the help of ultrasound and X-ray imaging [20]. This allows the radioactive sources (typically Ir-192 for HDR due to its
higher energy gamma emission) to pass directly to the treatment region of interest.
The use of a remote afterloader moves the radioactive sources through each catheter
into a predetermined location inside the prostate (dwell points). The time and position at which the source remains inside the prostate is determined by the treatment
planning system. Once the source has placed within all the required locations, it is
withdrawn so the patient is source free. HDR treatments are usually followed by
an additional treatment of external beam therapy, which can take approximately 4-5
weeks. The ability to alter the dose after the catheters have been inserted into the
prostate is one of the major advantages of HDR brachytherapy [20].
In LDR brachytherapy, low energy emitting seeds are inserted into the prostate in
a similar fashion to that of HDR treatments. Although for LDR treatments, metal
seed applicators are used to insert the individual seeds into the prostate. These seeds
become permanent fixtures inside the prostate and remained fixed in the inserted lo-
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cation (provided no migration within the prostatic tissue occurs). The radionuclide’s
used in LDR seeds are low energy gamma emitters which deliver continuous radiation to the treatment volume for the duration of their lifetime.
As LDR brachytherapy is the treatment option on which this study is based, it will
be discussed in further detail in the following section.

2.2.4

Low Dose Rate (LDR) Brachytherapy

Low Dose Rate Brachytherapy (LDR-BT) has become a common modality for the
treatment of localised prostate cancer [19]. Although external beam radiation therapy
(EBRT) and prostatectomy are as frequently used, LDR brachytherapy is the form of
treatment where prostatic calcifications may have a significant effect (high Z material
interaction with low energy gamma radiation).
LDR-BT can be delivered as a monotherapy, in which treatment is achieved using
permanent seeds alone, or in conjunction with external beam radiation therapy, in
which a course of external beam is delivered after seed implantation [17]. The Advantage of LDR brachytherapy over EBRT is its ability to deliver higher and more
conformal dosages to the prostate gland sparing surrounding normal tissue. In comparison to prostatectomy, seed implantation is a quick and has a lower complication rate during and after the procedure (bleeding, urinary incontinence, and impotence) [19].
In LDR treatments, three low energy gamma emitting radionuclide’s are commonly
used for seed treatment. These are I-125, Pd-103 & Cs-131 [19]. The selection of
the isotope and their localisation provides high dose deposits in the tumour and rapid
fall off outside the treatment area, preserving organs at risk [19]. I-125 is one of the
most commonly used LDR isotope in brachytherapy. It has a half life of 60 days and
emits x-rays with energies of 27.4, 31.4 and 35.5 KeV [15]. With these energies, and
low dose rates, I-125 seeds are considered relatively safe for live insertions [15]. A
cross section of a GE Healthcare model 6711 seed source is shown in Figure 2.4.
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As these isotopes will be used for future experimental research, they will be the only
source considered for the remained of this study.

Figure 2.4 The geometry of the GE Health Care model 6711 LDR Brachytherapy source [21]

The implementation of LDR treatments are steadily increasing however it remains an
exclusive treatment option unlike more conventional treatments. Its implementation
is also dependent on the individual patient’s case and therefore not all patients are
potential candidates for this form of treatment.
2.2.4.1

Procedure

In LDR brachytherapy, radioactive seeds are implanted inside the prostate gland and
remain inside for the remainder of the patient’s life (see Figure 2.5). The radioactive
source will continue to emit low energy gamma radiation for the duration of its active
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lifetime. Seed insertion is not a straight forward process and there are a number of
vital steps that need to be taken for successful treatment.

Figure 2.5 Seed insertion cross section [19]

Prior to operation, patients undergo bowel preparation and are treated with a course
of antibiotics. In the operating room, a patient is placed under general or spinal
anaesthesia [19]. An air filled gel is administered which is used to visualise the
urethra and differentiate the bladder from the prostate [19]. Measures are also taken
to keep the patients genitalia fixed from the radiation field using towel clips or tape
[19].
Trans-rectal ultrasound examination is undertaken to determine the shape and size of
the gland. This can be performed a few weeks prior to seed insertion (pre implant
treatment planning) or on the day (intraoperative treatment planning). The ultrasound
equipment is used in conjunction with an implantation template which acts as a guide
for needle insertion. The template is a square unit that sits against the perineum and
contains a uniform grid through which needles are inserted to control their spacing.
Both movement and location of the ultrasound probe and template is controlled by
the stepping unit. The stepping unit is designed to interface with user software in
order to facilitate interactive treatment planning.
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Once the bladder base to template distance has been identified, two stabilising needles are inserted posterior to the urethra and either side of the midline [19].
Because of movement of the prostate, during the procedure a pre-plan is created
in order to minimise the risk of positioning errors. [19]. The computing planning
system makes use of a loading pattern which is linked to the template stepping unit.
This provides the co-ordinates for insertion.
Once pre planning has been completed, 20 cm long 18 gauge needles are inserted
into the in the prostate. When both the post and pre plan have been consulted radioactive seeds are placed into the prostate using an applicator [22]. The position
of the implants is observed using fluoroscopy and ultrasonography, if there is any
cold spots detected, additional seeds can be added to cover them. The procedure is
finalised after a final CT scan of the prostate and post implant dosimetry has been
completed. Some centres perform post implant CT on the same day as the procedure
although this is most often performed one month after implantation. In the case that
post implant dosimetry indicates dose coverage is poor, the patient will need to be
booked in for further treatment e.g. an implant top-up. This implant treatment is a
one day procedure, however patients are usually discharged from hospital the next
day [22]. A cross sectional view of the treatment set up can be seen in Figure 2.6.

Figure 2.6 LDR-brachytherapy treatment set up and needle insertion [23]
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Long Term Results and Quality of Life

Quality of life has always been a major concern when selecting the appropriate treatment modality. This has been seen in recent years in which a number of patients place
equal emphasis on prostate cancer survival and post treatment quality of life [17].
Quality of life is now becoming an important factor when selecting the appropriate treatment of localised prostate cancer. The three main domains of bother after
localised prostate cancer treatments are sexual, urinary and bowel function [17].
I-125 Brachytherapy patients have shown to have a significantly better sexual function after treatment over patients who have undergone high dose EBRT or radical
prostatectomy [24]. Voulgaris et al. found that 84% of men who were potent before LDR treatments retained their potency regardless of the technique employed
for implantation [17]. Their study also found that urinary complications were lower
with LDR treatments. Less than 1% of patients reported issues concerning incontinence [17].
Although patients who undergo radical prostatectomy report higher complications
concerning sexual and urinary function, it has been found that bowel function and
bother (diarrhoea and rectal bleeding) are not as significant as those patients undergoing radiotherapy (LDR-BT and EBRT) [25]. It is important to note that these
studies do not distinguish monotherapeutic brachytherapy from brachytherapy used
in combination with EBRT.
Quality of life is a subjective matter which depends heavily on the individuals needs.
If the decision was based with only sexual function and continence in mind, I-125
Permanent Prostate brachytherapy implants would be the most favourable treatment
option [17].
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Prostatic Calcifications
General Calcifications

Calcifications are small hard objects caused by the build up of calcium salt in soft
tissue (see Figure 2.7). Although they can be found in numerous sites of the body,
they are of some concern in organs where cancer development is common, such as the
breast and prostate. Calcifications are diagnosed using various imaging modalities
such as ultrasound, CT and even MRI, however it is most easily found during surgical
removal of tissues in which they are contained [26].

2.3.2

Calcification Formation in the Prostate

Prostatic calculi are formed from calcareous material deposited within the tissues or
acini of the prostate gland [27]. These bodies are often associated with inflammation
of the prostate and it is has been suggested that they may be accountable for the
development of genital and urinary infection [28]. These formations are found to
be either sparsely distributed around the prostate or concentrated into lumps [29]. It
has also been found that prostatic calcifications are more commonly found in older
men [30] than younger men [29].
Calcification formation has been known to occur for many years, however the mechanism in which they formed is not clearly understood. It is believed that calcification
formation arises through two mechanisms, both of which are based on obstruction
and stasis of prostatic fluid. The mechanisms involved include calcification of existing corpora amylacea and the precipitation of prostatic secretions [31]. The theory
of calcified corpora amylacea is the most supported amongst pathologists. These are
small round or ovid bodies seen in the lumen of the prostatic acini, which may be
derived from desquamated epithelial cells and proteinaceous material [26].
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Figure 2.7 Patterns and degrees of calcification in benign prostatic tissue: (A) mild calcification in prostatic gland and stroma (inset); (B) moderate calcification in prostatic glands; (C)
severe calcification with section damage [32]

2.3.3

Calcifications and Prostate Cancer

Relatively little is known about the relationship between calcifications and cancer
development, however it has been proposed that calculi may be associated with the
formation of prostatic hyperplasia and carcinoma [27].
Hwang et al. [28] proposed to find the relationship between prostatic calculi and
prostate cancer using prostate biopsy specimens in a vast group of Korean men. 471
individual patient studies were carried out using either transrectal ultrasonography
(TRUS) or prostate biopsies. Patients were separated into two different groups based
on their condition. These two groups consisted of patients with developed prostate
cancer and patients with benign prostatic hyperplasia. Using the 471 samples, correlations between prostate cancer risk and age, serum total PSA levels, prostate volume,
and prostatic calculi were analysed [28]. Whilst patients with prostate calculi had on
average higher Gleason scores, the results were not conclusive enough to show that
these prostatic calcifications increased the risk of prostate cancer. Results did however find that calculi were more common in men with the prostate cancer and it was
also found that patient age, serum total PSA and prostate volume were risks factors
for prostate cancer development [28].
Calcifications are found in several regions of the prostate and even the ejaculatory
system. Suh et al. [32] investigated the occurrence of calcifications and the spe-
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cific zones of the prostate where they are situated. Using whole mount sections
of 298 consecutive prostatectomy and cystoprostatectomy specimens, calcifications
were found in the central, peripheral and transition zones, and verumontanum, ejaculatory ducts, and seminal vesicles. Results found 88.6% of specimens contained
calcifications in the prostate and ejaculatory system, 58.1% in the seminal vesicles
and 17.1% in the ejaculatory ducts [32].
Although calcifications were observed in all zones of the prostate, they occurred most
frequently in the transition zone, with findings showing that calculi occurred more
frequently in benign glands and hence a closer association to benign prostatic hyperplasia than prostatic adenocarcinoma. Calcifications in the verumontanum were also
frequently found in the series with an occurrence of 67.1% [32].
Studies have also looked at the links between calcification and chronic pelvic pain
syndrome (CPPS), as a number of young patients have been found with significantly
calcified prostates [30]. Results found that prostatic calcifications are common in patients with CPPS and are also associated with greater inflammation, bacterial colonisation, and symptom duration [30].

2.3.4

Composition

From numerous studies, calcifications in the body have been found to be of varying compositions. This makes the analysis of calcification composition an important
part of clinical treatments. If variations in prostatic calcification compositions occur, it may be possible that the attenuation effects will vary considerably in patient
treatments.
Breast calcifications are classified using two categories known as Type I and Type II.
Type I calcifications are composed of calcium oxalate (weddellite - calcium oxalate
dihydrate & Whewellite - calcium oxalate monohydrate), whilst Type II calcifications
have a reasonable amount of phosphorus content in their composition (Most typically
hydroxyapatite). It is acknowledged that the finding of a type II calcification is most

Literature Review

24

commonly an indication of breast carcinoma, whereas a type I finding is usually
indicative of begin lesions [33].
Studies conducted by Hsu et al. [27] looked at the composition of prostatic calculi using Fourier Transform Infra-red (FTIR) microspectroscopic mapping and traditional
FTIR and Raman microspectroscopy. Using nine calcification samples from patients
with benign prostatic hyperplasia, the methods were compared and compositions
analysed.
Using traditional FTIR microspectroscopy, results established that the samples composition was predominately carbonated hydroxyapatite; however there was also a significant amount of calcium oxalate present in a number of the samples [27]. Raman
spectral results found similar results as both hydroxyapatite and calcium oxalate were
identified, however the Raman spectral technique was able to differentiate calcium
oxalate into calcium oxalate mononhydrate (COM) and calcium oxylate dihydrate
(COD). The problem with traditional methods lie with the time required to achieve
the chemical composition analysis, and in regards to traditional FTIR microspectroscopy, the detection of uncertain components [27]. FTIR microscopic mapping
improved on this through point-by-point analysis and was capable of detecting all
complicated components of prostate calculi. Although advantageous in characterising prostatic calculi composition in this application it noted that more studies are
required for FTIR microscopic mapping [27].
It appears that hydroxyapatite is an integral component of calcification structure.
The similarities between breast calculi and prostate calculi suggest there is little variance of these processes throughout the body and therefore don’t appear to be organ
dependent. However, there is a possibility that these formations will vary slightly in
elemental quantities. Bayraktar and Tas synthesised hydroxyapatite powders through
a novel chemical precipitation technique using synthetic body fluids. Results found
that the powders contained trace amounts of Na and Mg impurities due to the use of
synthetic body fluids (instead of pure water) used in the precipitation technique [34].
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It is likely that there will be a number of trace elements contained in calculi developed
within the prostate. This will be an area of interest in the following chapter.

2.3.5

Clinical Importance of Calcifications in LDR Treatments

There have been minimal findings to suggest that prostatic calcifications have a significant impact of LDR treatment planning, however the consensus amongst doctors
and physicists at St George Cancer Care Centre is that there is substantial dose depreciation in the zones of serious calcification formation. Depending on the locations
of theses formations, calcifications may provide a dose shielding to the urethra or
rectum due to the attenuation of the low energy radiation passing through the high Z
calcification material. The effect of this can be beneficial for the sparing of normal
tissue around these critical structures; however dose reductions in these areas can
also lead to a fall in the tumour control probability (TCP).

2.4

Dosimetry

Radiation dosimetry deals with the measurement of the absorbed dose, or the dose
rate resulting from the interaction of ionising radiation events in matter [13]. The
term dosimetry refers to the determination any radiologically equivalent quantity.
Dosimetry is mostly concerned with the determination of the absorbed dose, which
is described as the expectation value of the energy imparted to matter per unit mass
at a point [13]. When concerning radiation doses being received by patients, it is
essential to measure the absorbed dose as accurately as possible to optimise the radiation procedure. Dosimetric quantities will be a strong focus of the study and will
be referred to frequently when describing the results found from the measurement of
brachytherapy doses and the dose perturbation caused by calcification bodies.
There are a wide variety of radiation detectors developed specifically for the purpose of measuring the absorbed dose or dose rates. These are known as dosimeters.
As each dosimeter is developed for a specific purpose, it is essential to select the
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dosimeter that suits the requirements of the desired application. Due to the nature of
this study only the dosimeters employed for the dosimetry of therapeutic photons are
discussed.

2.4.1

Dosimeters

Unfortunately, except for calorimetry, no other dosimeter detects absorbed energy
directly and therefore radiation effects such as ionisation and chemical changes are
used to assess the impact of radiation on tissues [15]. These measured effects are then
converted into absorbed dose values using various conversion techniques. The ideal
dosimeter characteristics include: Accuracy, precision, detection limit, measurement
range, dose response, dose rate dependence, tissue equivalence and spatial resolution [15], however real life dosimeters do not satisfy all of these requirements. No
single dosimeter has a direct advantage over another as each has their own benefit for
the required application. Common X-ray dosimetric techniques include air filled ionisation chambers, semiconductors, thermoluminescence detectors, film, calorimeters,
diamond detectors, chemical dosimeters, gel dosimeters and biological dosimeters.
2.4.1.1

Semiconductor Detectors

The developments of semiconductor based detectors have provided a number of possibilities for the use of solid state dosimetry for ionising radiation. The energy required to induce electron-hole pairs in semiconductor detectors is 10 times lower
than conventional ionisation chambers [15], which provides a number of benefits.
Firstly, these detectors can be designed with a small active area, allowing in-vivo
dose measurements to be conducted. Secondly, these detectors provide useful applications in low energy photon measurements due to the low energy required to create
ion pairs. Other advantages of semiconductors detectors include the ability to work
in unbiased (passive) and biased (active) modes, high efficiency of charge collection at low voltages and highly reproducible in large batches [35]. Problems with
semiconductor detectors include cost of production and their limited applications in
radiotherapy [15]. The metal oxide semiconductor-field effect transistor (MOSFET)
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allows useful dosimetric investigations in a number of applications due to its small
physical size.
2.4.1.2

MOSFET Detectors

The MOSFET detector consists of four main terminals which are: source, gate, drain
and body. The body of the MOSFET (also known as the substrate) is often connected
internally to the source terminal and therefore is often presented as a three terminal
device. The structure of a simple MOSFET is shown in Figure 2.8.
MOSFET dosimetry is based on the generation of electron-hole pairs (energy production of one e-h pair in silicon oxide is about 18 eV) in the silicon oxide layer of
the MOSFET structure due to incident ionising radiation [36]. The generated positive charges move in the direction of the Si-SiO2 interface where they are captured
on traps and hence create a positive build-up charge. [36]. This positive charge effectively changes the voltage required to drive a fixed current between the source and
drain (threshold voltage) [36].
The MOSFET can operate under two modes, these being passive (no gate bias voltage) or active (positive gate bias voltage). Applying a positive gate bias effectively
reduces the recombination of produced e-h pairs in the silicon oxide layer and therefore the response of MOSFET becomes more linear and sensitive. In active mode,
the dose response is essentially linear over a wide dose range and depends on the
oxide thickness, electrical field in the oxide and technology of the oxide growth [36].
Typical MOSFET structures have an effective area of less than 0.1 mm2 and show
sensitivities in the range 10-1000 mV/Gy [14].
The MOSFET detector has many advantages that make it attractive for clinical in
vivo dosimetry. Such characteristics are [36]:

1. Extremely small size of dosimetric volume, which is very difficult to obtain
with other detectors.
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Figure 2.8 Configuration of a MOSFET adapted from [14].

2. Permanent dose accumulation storage and read out without deterioration of the
dose information.
3. Dose-rate independent.
4. Adjustable sensitivity, making them suitable for many radiotherapy applications

Although useful for many uses, when using MOSFETs, considerations must be made
upon the thermal stability, energy dependence, angular response, linearity and reproducibility of the MOSFET response. More details of the MOSFET can be found via
Rosenfeld et al [36].
2.4.1.3

MOSkinTM Detector

The MOSFET detector that will be employed for phantom measurements undertaken
in Chapter 4 is a MOSkinTM detector, developed by the CMRP and shown in Figure
2.9. The MOSkinTM consists of a 0.55-1 µm thick silicon oxide layer, a 350 µm thick
chip and a 0.07 mm water equivalent Kapton cover. Through these specifications,
the detector can be aligned in close proximity to the phantom and hence provide
close range point dosimetry analysis. There are some disadvantages involved with
the use of the MOSkinTM which includes long measurement time for charge collection to achieve adequate results and its ability to only measure point charges. The
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MOSkinTM is, however, the most appropriate for measuring small doses very close to
the surface. This has been shown through in the work of Kwan et al. [37] in which
the MOSkinTM was implemented to determine the rectal doses measured during HDR
brachytherapy treatments [37].

Figure 2.9 MOSkinTM Detector (patented [38]).

2.4.2

Dosimetry for LDR Prostate Brachytherapy

2.4.2.1

TG-43 Dosimetry Protocol

Due to the vast number of reports concerning dosimetry data, in 1988 the Radiation
Therapy Committee of the American Association of Physics in Medicine (AAPM)
formed task group No.43 [39]. The purpose of this task group was to review the recent documentation of interstitial brachytherapy sources and recommend a dosimetry
protocol including the formalism for dose calculations and a data set for the values of dosimetry parameters [39]. In 1995 the AAPM released the TG-43 Protocol [39] outlining the task group’s recommendations. Due to the development of
new brachytherapy seeds, the AAPM released an update [40] in 2004, which included updated source data and corrections to the existing formalism. A Supplement
to the 2004 AAPM TG-43 update was released in 2007 due to the availability of new
low energy photon emitting brachytherapy sources on the market [41].
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2D Formalism
The TG-43 protocol is based on both measured and interrelated quantities, while also
allowing calculations for two-dimensional dose distributions around sources [39]. As
brachytherapy seeds are cylindrically symmetrical, the dosimetry for brachytherapy
seeds can be considered in two dimensions. The AAPM recommendation for the 2D
dose rate around a brachytherapy source is given as:

Ḋ(r, θ) = SK Λ

GL (r, θ)
gL (r)F (r, θ)
GL (r0 , θ0 )

(2.3)

[40]
Where r is the distance in cm from the point of interest to the centre of the radioactive
source, θ is the polar angle subtended from the horizontal source plane and the line
joining the point of reference to the centre of the radioactive source, (r, θ) is the coordinate of the point of interest, Ḋ(r, θ) is the dose rate at the point of interest, SK is the
air kerma strength, Λ is the dose rate constant, GL (r0 , θ0 ) is the geometry function,
gL (r) is the radial dose function and F(r, θ) is the anisotropy function. The coordinate (r0 , θ0 ) is the calibration reference point, and is recommended to be at the point
(1cm, 90◦ ) (See Figure 2.10). A function accompanied by the subscript L indicates
that the line source approximation for seed geometry is used to generate data for the
function. If the point source approximation is used, the subscript P is indicated in the
function. As the data generated by the two approximations vary, it is important that
the appropriate data is selected according to the geometry approximation employed.
For more information on individual parameters i.e. air kerma strength, dose rate
constant, geometry factor, radial dose function and anisotropy function, see [40].
2.4.2.2

Clinical Dosimetric Parameters

In the clinical environment, the quality of LDR brachytherapy treatments in the
prostate is specified using dosimetric parameters. These parameters allow for the
comparison and analysis of patient treatments, providing dosimetric calculation. The
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Figure 2.10 TG-43 Coordinate System [39].

dosimetric parameters currently assessed to determine the quality of individual brachytherapy treatments include source activity, minimum tumour dose, D90 , D100 , V90 , V100 ,
V150 , V200 and dose volume histograms [42], [43]. These parameters are related to
the prescription dose for prostate and the clinical target volume (CTV). The prescription dose is the intended dose to the 100% isodose, and for I-125 brachytherapy treatments, the prescription dose is 144Gy according to Task Group 43 formalism [44].
For the CTV, the following conditions correlate with a good pre-implantation dosimetry [43]:
The V100 (the percentage of the CTV that receives at least the prescribed dose) must
be at least 95% (V100 > 95% of CTV).
D90 (the minimum dose received by 90% volume of the CTV) will be larger than the
prescription dose (D90 > 100% of prescription dose).
The V150 is the percentage of the CTV that receives at least 150% of the prescription
dose. This should be equal to or less than 50% of the CTV.
For organs at risk (OAR)
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Rectum: The primary parameter D2cc (minimum dose to the most exposed 2 cm3 of
the OAR) must be less than reference prescription dose.
Urethra: The primary parameter D10 must be less than 150% of reference prescription
dose.
Post-implant analysis includes the outline of the target volume as well as construction of dose volume histograms (DVHs) constructed for this target volume. DVHs
are plots of cumulative dose-volume frequency distributions [45]. Post-implant evaluation also requires documentation of the dose levels that cover 100% and 90% of the
target volume, i.e. D100 and D90 , and the fractional volume receiving 200%, 150%,
100%, and 90% of the prescribed dose, i.e. V200 , V150 , V100 , and V90 [43].
DVH’s and dosimetric parameters are useful for clinical treatments; however these
values make the assumption that tumour cells are uniformly distributed in the clinical
target volume.

2.4.3

Calcification Dosimetric Effect

The low energy photons emitted by the brachytherapy source used in LDR brachytherapy treatments interact with matter heavily through the photoelectric effect. This is
significant when considering calcifications as the cross section of this interaction is
scaled approximately as Z4 , where Z is the atomic number of the element of interest.
As a result of the I-125 low photon energies (27.4, 31.4 and 35.5 KeV [39]) and high
Z composition of the calcification, attenuation becomes an issue.
Carrier et al. [46] studies used Monte Carlo simulations to evaluate the impact of
interseed attenuation for I-125 permanent seed implants. Using four different dose
calculation techniques, comparisons found that seed density has a considerable influence on interseed attenuation. A plan with a typical low seed density of 42, 0.6 mCi
seeds, in a 26 cm3 prostate suffers a 1.2% drop in the CTV D90 value due to interseed
attenuation. While for the same prostate volume, a drop of 3.0% is calculated for a
higher seed density of 75, 0.3 mCi seeds [46].
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Landry et al. [47] looked at the dosimetric impact of gold fiducial markers (FM)
in patients receiving combined external beam and LDR seed treatment. Large dose
reductions were observed at the distal side of the FM, while at the proximal side a
dose enhancement was observed. In clinical cases, the FM reduced the dose to some
voxels by up to 50% and generated shadows with extents of the order of 4 mm [47].
Inside the prostate contour, cold spots relating to less than 95% of the prescription
dose were found in the order of 20 mm3 . These findings suggest FMs cause a major
local impact on dose distributions in LDR brachytherapy treatments and therefore
could be accountable for reduced tumour control [47].
As a result of these findings, it is understood that calcium bodies will have a similar
effect and therefore may result in dose perturbations in LDR brachytherapy treatments when contained within the prostate. This is also assumed from the high attenuation of low energy photons through calcium (high component of calcification
composition) in comparison to that of water (equivalent to human tissue)as shown in
Figure 2.11.

Figure 2.11 X-Ray Mass Attenuation Coefficients and Mass Energy-Absorption Coefficients
for calcium and water [48].
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Geant4 Simulations

Geant4 [49, 50] is a widely used Monte Carlo code for medical physics applications.
In this project, it was used to evaluate quantitatively the dosimetric effect of prostatic
calcifications in real clinical treatments.
Although Geant4 was born as a Monte Carlo simulation toolkit for high energy
physics applications, due to its flexibility and openness to evolution, it has been extended to other physics research domains such as space science and medical physics.
Currently, Geant4 is the only open-source, free and general Monte Carlo code for
radiation physics research, from high energy physics down to eV scale [51].
The capabilities of Geant4 include [51]:

• Geometrical modelling of experimental set-ups as well as the ability to define
materials and particles involved, including their physical interactions.
• Modelling of electromagnetic and hadronic interactions. Alternative and complementary physics models are available.
• Particle tracking in matter, also in the presence of electromagnetic fields.
• Modelling of detector response.
• Graphical User Interfaces.
• Visualisation of experimental set-up, particle tracks and hits.
• Analysis component (histograms, ntuples, etc.).

Geant4 was adopted in this study as it allows to model complex geometries, coupled
with extensive physics functionality. In particular it is possible to:

• Model brachytherapy sources and prostatic calcifications in terms of geometry
and materials.
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• Describe accurately inhomogeneous media based on elemental composition
and density.
• Describe in detail the electromagnetic interactions of particles with matter, of
interest for this study.
• Calculate the energy deposition in 3D, deriving from the interactions of primary and secondary particles.

The Geant4 Livermore Package was adopted in this work to model the electromagnetic interactions of particles with matter. This package was validated against NIST
reference data in [52].

2.5.1

Prostatic Calcification Studies using Monte Carlo

As previously stated, there has be a number of studies which have looked at interseed
attenuation and the effect of prostatic tissue using Monte Carlo simulations [46], as
well as the effect of gold fiducial markers implanted for combined brachytherapy and
external beam treatments [47].
In 2005 Chibani et al. [53] developed an accelerated Monte Carlo code, Monte Carlo
dose calculation for prostate implant (MCPI) to quantify the dosimetric effects of not
only interseed attenuation and tissue composition but also the effects of calcifications
found in prostatic tissue.
The MCPI code implemented several new transport simulation techniques to dramatically increase speed in comparison to other general purpose codes. Utilising a
hybrid geometry model, seeds and voxels could be handled simultaneously, unlike
other Monte Carlo codes which normally treat theses separately. The cylindrical
symmetry of the internal seed geometry also allowed for discrete modules to be used
in the code, this was essential for the increased speed capabilities of the code. The
MCPI code physically simulates a set of radioactive seeds with arbitrary positions
and orientations, merged in a three-dimensional heterogeneous phantom represent-
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ing the prostate and surrounding tissue [53].
To illustrate its usefulness, the MCPI code was used to investigate the dosimetric
effects of interseed attenuation, tissue composition, and tissue heterogeneity [53].
For a 103-Pd based preimplant plan it was identified that interseed attenuation and
slightly varied prostatic tissue composition accounted for a 6% decrease of D100 [53].
In the study it was found that the inclusion of prostatic calcifications accounted for
much larger reductions to the dosimetric parameters. Calcifications covering 1%-5%
of the prostate volume were studied for two patients. This included a preimplant consisting of 67 Pd-103 seeds and a postimplant consisting of 97 I-125 seeds. For both
cases, the value of D100 was reduced by as much as 25% for a 1% calcified prostate.
When considering a prostate volume consisting of 5% calcification occupancy, D80 ,
D90 , and D100 were decreased by up to 32%, 37%, and 58%, respectively [53].

Chapter 3
Calcification Analysis
3.1

Introduction

Calcifications are a common manifestation in the prostate and are possibly unique
to each individual. By removal of the prostate gland through radical prostatectomy,
calcifications can be extracted from tissue for use in various studies. These individual
calculi or stones have noticeable variances such as size, number, cluster formation
and possibly composition, which will be explored through µ-PIXE studies.
In this chapter prostatic calculi/stones were obtained from surgically removed prostates
and analysed. Four pathological patient samples were obtained, each containing a
varied number and size of stones in the set which were measured directly. Taking
only one significant size stone from each patient set, the heavy elemental composition information of the calcification sample was obtained through µ-PIXE. These
components will have the greatest impact on dose perturbations in LDR-BT treatments and therefore special attention is paid to these characteristics.

3.2

Pathological Samples

Since pathological samples vary greatly, it is difficult to obtain enough samples that
will provide a conclusive analysis of variation among all patients. The strategy taken
37
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in this study consisted of analysing and comparing the characteristics of a limited
number of calcifications to achieve a reasonable assessment on the possible variation
of number, size, composition of the sample.
Clinical samples were obtained from patients undergoing radical prostatectomy and
were supplied by Douglas Hanly Moir Pathology. Four patient samples were provided for the study, with the ages of patients ranging from 68 to 79 years of age.
Each specimen had a significant change in appearance with noticeable changes in
size and number. The size of every calcification specimen within the set was measured using electronic callipers to an accuracy of 0.01 mm. Pathological calcification
sample sets can be seen in Figure 3.1 for patient 3 and 4

Figure 3.1 Calcification Samples of Patient 3 and 4

Four stones (one from each patient sample set), as seen in Figure 3.2, were selected for micro particle induced x-ray emission (micro-PIXE) testing using the
Heavy Ion microprobe at the Australian Nuclear and Science Technology Organisation (ANSTO). This was used to analyse the heavy elemental composition of the
calculi. Images of the 4 patients samples used for testing were taken using an Olympus microscope at ANSTO before measurements on the microprobe were conducted.
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Figure 3.2 Calcification patient samples: A) Sample 1 Dim:1.57 mm × 1.93 mm × 0.43 mm
, B) Sample 2 Dim:1.14 mm × 1.19 mm × 0.91 mm, C) Sample 3 Dim:1.56 mm × 2.39 mm
× 1.51 mm, D) Sample 4 Dim:2.50 mm × 3.20 mm × 2.34 mm

3.3

3.3.1

Micro Particle Induced X-Ray Emission (µ-PIXE)
Testing
Introduction to PIXE

Particle induced x-ray emission (PIXE) is a widely used technique that is capable of
measuring a number of elements simultaneously with a high sensitivity [54]. It can be
used to determine the elemental make up of a number of materials. This technique
is non invasive, quick and reliable with highly accurate results being yielded in a
number of studies.
When a sample of a material is exposed to an ion beam, x-rays characteristic of ele-
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ments within a sample are emitted due to atomic de-excitation. These characteristic
x-rays are detected and provide information on elemental composition of the sample. PIXE is non destructive, therefore the chemical and physical properties of the
analysed sample remain unaltered.
An extension of PIXE in which focused microbeams (1 µm) are used is called microPIXE or µ-PIXE. µ-PIXE can not only provide information on elemental make-up
but is also capable of finding the 2D distribution of trace elements [54]. Through
PIXE analysis elemental distribution maps are built which can be used to determine
the homogeneity of a sample.
A number of studies have been conducted using the µ-PIXE technique. Garman and
Grime [55] used µ-PIXE to quantify the metal content of protein molecules with a
relative accuracy between 10% and 20% [55]. µ-PIXE has also been extensively used
in environmental and biological research to map trace elements in plant and animal
tissues. Siegele et al. [54] used µ-PIXE techniques to study the localisation of trace
metals in metal-accumulating plant tissues. The group was successful in mapping
trace metals across leaf tissue and their sites of accumulation with a resolution of
5µm using µ-PIXE studies on the ANSTO Heavy Ion Microprobe. This is shown in
Figure 3.3

Figure 3.3 Elemental maps of K (a), Ca (b) and Ni (c) taken on a hand-sectioned cryo-fixed
freeze-dried Hybanthus floribundus subsp floribundus leaf. [54]

Shimizu et al. [56] used µ-PIXE analysis to assess secondary pulmonary alveolar
proteinosis (PAP) specimens. This disease is caused by the inhalation of harmful
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particles which can be detected in the specimens through this type of testing [56].
The group identified the location and elemental make up of the particles in each specimen simultaneously and were able to detect magnesium (Mg), aluminium (Al), silicon (Si), phosphorus (P), sulphur (S), scandium (Sc), potassium (K), calcium (Ca),
titanium (Ti), chromium (Cr), copper (Cu), manganese (Mn), iron (Fe), and zinc
(Zn) [56]. One problem lies with the µ-PIXE technique and that is its inability to detect lighter elements within a sample. For this purpose another technique known as
particle induced gamma-ray emission (PIGE) can be used for the detection of lighter
elements. The PIGE technique is similar to PIXE although it is achieved through the
analysis of gamma rays induced with charged particles.

3.3.2

Experimental Set Up

One major aim of the experiment conducted within this project was to determine
the heavy element components of the calcification samples. These trace elements
are of significance as high atomic number elements will increase the probability of
photoelectric absorption events, therefore contributing significantly to the attenuation of photons, eventually affecting the clinical outcome of the LDR brachytherapy
treatment.
µ-PIXE analysis was undertaken at the Australian Nuclear Science and Technology
Organisation using the ANSTO High Energy Heavy Ion Microprobe (HIMP), as used
by Siegele et al. [54]. The HIMP uses a 10 MV Tandem accelerator in which ions
can be accelerated to the MeV energy range. In this analysis a 3 MeV proton beam
with typical spot size between 5 and 10 µm was used.
At this spot size, beam currents between 0.4 and 0.5 nA can be achieved, which is
sufficient for µ-PIXE analysis. A high-purity Germanium (Ge) detector was used
with a 100 mm2 active area to measure the characteristic X-rays emerging from the
calcification samples. The detector was located 100 mm from the sample to reduce
pile up due to the high count rate. A 100 µm Mylar foil was used to reduce low
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energy X-rays count as well as prevent scattered protons from entering the detector.
Samples were fixed to the sample holder in Figure 3.4 by means of double sided
carbon tape. This tape is clean and does not contain trace elements higher than
oxygen (Z>8). The tape does not affect measurements and is effective in holding the
samples providing good electric conductivity to allow target current measurement.
Each sample was then scanned for approximately 20 minutes to allow extensive data
to be obtained.

Figure 3.4 ANSTO Heavy Ion Microprobe sample holder containing the four samples used
for Micro-PIXE analysis

The average elemental concentration in the samples were calculated using GeoPIXE
[57], [58]. Figure 3.2 shows that the calcification samples are very irregular in shape.
In µ-PIXE samples should be very flat, otherwise a shadowing effect can be observed
in the elemental map. This is clearly visible in sample 2 in Figure 3.5. In order to
get a representative concentration from the maps only areas without shadowing were
integrated. These outlined areas are shown on the calcium maps for the four samples
in Figure 3.5.
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Figure 3.5 The four selected regions used for concentration analysis on each calcification
sample: (A) Region for sample 1, (B) Region for sample 2, (C) Region for sample 3, (D)
Region for sample 4

3.4
3.4.1

Results
Sizing of Calcifications in Pathological Sample Sets

Sample Set 1: In this set, 4 moderate size stones were found. The largest stone in
the set had a dimension of 3.7 mm× 2.17 mm× 1.23 mm and the smallest being 0.8
mm× 2 mm× 0.5 mm. The stones were off whitish in appearance and had a pancake
like formation, there were no clusters seen in this sample and each stone was easy to
distinguish and measure.
Sample Set 2: The stones seen in this set were smaller in both number and size,
as there were only 2 individual stones in the sample, with calculi approximately 1
mm in diameter. These stones appeared to be more spherical in appearance than
those found in patient 1. These stones were also darker in colour than those found in
sample 1.
Sample Set 3: The 3rd patient’s stones were unusual in comparison to the first two
samples, as there were 29 different stones present; the largest dimension was 2.03
mm×2.18 mm×1.73 mm whilst the smallest has a spherical form with a diameter of
0.5 mm. There seemed to be a significant change within the sample as many of the
larger stones had an egg or pancake-like shape while smaller stones were spherical
as seen with sample 2.

Calcification Analysis

44

Sample Set 4: showed multiple small dark stones clustered together. It was extremely difficult to measure the size of various stones under 0.5 mm in diameter
however there were still a number of large easily distinguished stones that could be
measured, the largest of these being 2.50 mm×3.20 mm×2.34 mm. In the set there
were 27 distinguishable stones (greater than 0.5 mm in diameter), while the total
number of bodies seen was over 80. Most of these smaller bodies were grain-like in
appearance. The colour of these stones were black when viewed without microscopic
aid, which was interesting as the other samples appeared to have similar colouration
in comparison to these very dark stones. A singular stone from sample 4 is shown in
Figure 3.6.

Figure 3.6 Scale of significant sized calcification in Patient 4

Although there were many differences in the samples such as colour cluster size and
number of stones, there was a similarity in the formation of the stones. None of the
samples contained stones larger than 3 mm in diameter although stones of these sizes
have been identified on patient ultrasound images by physicists at St George Cancer
Care Centre. It was also seen that larger sized calculi had an irregular shape while
smaller calculi where spherical.
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Prostate Calcification Compositions

Using the knowledge from the literature [27], it is assumed that the calcification samples are predominately hydroxyapatite formations, however this is not known and it is
possible that elemental variations in these samples may occur. These measurements
were conducted to understand this relationship as the percentage of heavier elements
in individual calculi may be significant in dosimetric outcomes for LDR brachytherapy treatments. The results were achieved by selecting regions of the µ-PIXE images
and taking the concentrations within these regions (as seen in Figure 3.5). Through
this analysis technique, it is not possible to determine the exact composition of the
sample as compounds and light elements cannot be measured. It is possible however,
to determine the heavy elemental concentrations in the selected region and derive an
approximation of the composition and components from these findings.
Results from the Heavy ion microprobe found the following components were present
in most of the samples phosphorus (P), sulphur (S), chlorine (Cl), potassium (K), calcium (Ca), iron (Fe), zinc (Zn), and strontium (Sr). Bromine (Br) was also detected
but in such low concentrations (very low parts per million range) that the contribution this element was insignificant. The image maps consisting of each individual
elements contained in the sample can be found in Appendix A.
The specific concentration of the elements contained in each sample were found as
follows.
Sample 1: These results (Table 3.1) indicate that the calcification in this sample
is high in both calcium and phosphorus which contribute to over 60% of the total
sample. It can also be seen that approximately 10% is made up of zinc. These
three elements dominate the make up (neglecting lighter elements) and considering
the ratio between calcium and phosophorus, indicate that hydroxyapatite is a likely
composition for this sample.
Although other elements are present, these amounts are extremely low and may ac-
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count for organic materials contained around or within the sample. The image map
shown in Figure 3.7 identifies the concentration percentage and distribution of phosphorus, calcium and zinc throughout sample 1.
Table 3.1
Elemental concentrations in the selected region of Sample 1. Note: percentages do not add
to 100% as lighter elements cannot be detected.

Element
(Name)
Phosphorus (P)
Sulphur (S)
Chlorine (Cl)
Potassium (K)
Calcium (Ca)
Iron (Fe)
Zinc (Zn)
Strontium (Sr)

Atomic No. Concentration
(#)
(%)
15
23.083 ± 4.617
16
0.293 ± 0.059
17
0.444 ± 0.089
19
0.062 ± 0.012
20
39.549 ± 7.910
26
0.007 ± 0.001
30
7.744 ± 1.549
38
0.035 ± 0.007

Figure 3.7 Distribution and concentration percentage for phosphorus, calcium and zinc in
Sample 1.

Sample 2: The concentrations of the 2nd sample (Table 3.2) were similar to that of
sample 1, although a variance was seen with slightly higher phosphorus content and
a reduced calcium percentage. It was also seen that the zinc content was reduced
in comparison to sample 1. Most notably, potassium levels increased considerably,
however it was still only accountable for less 1% of the composition. As with sample
1, the remaining elements were found in minor concentrations. Overall it is seen that
sample 2 shares similar quantities to those in sample 1. It could be assumed that both
samples were derived in a similar manner and therefore hydroxyapatite is a likely
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composition for this sample as well. The percentage concentrations and distribution
of phosphorus, sulphur, zinc and calcium are shown in Figure 3.8.
Table 3.2
Elemental concentrations in the selected region of Sample 2. Note: percentages do not add
to 100% as lighter elements cannot be detected.

Element
(Name)
Phosphorus (P)
Sulphur (S)
Chlorine (Cl)
Potassium (K)
Calcium (Ca)
Zinc (Zn)
Strontium (Sr)

Atomic No. Concentration
(#)
(%)
15
24.887 ± 4.977
16
0.338 ± 0.068
17
0.241 ± 0.048
19
0.835 ± 0.167
20
35.564 ± 7.113
30
3.038 ± 0.608
38
0.026 ± 0.005

Figure 3.8 Distribution and concentration percentage of phosphorus, sulphur, zinc and calcium in Sample 2.
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Sample 3: The results from the 3rd sample (Table 3.3) indicate that this sample was
quite different to the previous two samples. considerable reductions were seen in
the concentrations of zinc (0.4%), phosphorus (1%) and calcium (27%)to a lesser
extent. Through comparisons of the calcium/phosphorus ratio and the low overal
percentage, it was considered that this sample may be composed of a oxygen rich
calcium compound, such as calcium oxalate, rather than the phophorus dependant
hydroxyapatite.
In this sample, the amount of sulphur, which has been negligible in previous samples,
increased to 3%. This finding suggest organic materials are contained within the
stone. Although of little significance, it was also found that the concentration of iron
was much higher than found in sample 1.
Figure 3.9 shows the concentration percentage and distribution of phosphorus, sulphur, zinc & calcium in the sample.
Table 3.3
Elemental concentrations in the selected region of Sample 3. Note: percentages do not add
to 100% as lighter elements cannot be detected.

Element
(Name)
Phosphorus (P)
Sulphur (S)
Chlorine (Cl)
Potassium (K)
Calcium (Ca)
Iron (Fe)
Zinc (Zn)

Atomic No. Concentration
(#)
(%)
15
1.052 ± 0.210
16
2.684 ± 0.537
17
0.699 ± 0.140
19
0.256 ± 0.051
20
27.068 ± 5.414
26
0.012 ± 0.002
30
0.464 ± 0.093
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Figure 3.9 Distribution and concentration percentage of phosphorus, sulphur, zinc and calcium in Sample 3.

Sample 4: In the final sample analysed using the microprobe (Table 3.4), the concentration of calcium, phosphorus and zinc were again the most dominant.
It was also found that this sample (similar to sample 3) contained a significant amount
of sulphur, with roughly 3% contributing to the total composition. The ratio between
calcium and phosphorus suggests that this sample is close to those of sample 1 and
2, however, the overall reduced quantities may account for a strong presence of undetected light elements, such as oxygen. The increased sulphur levels suggest that
organic materials are also present in this stone.
The image map shown in Figure 3.10 identifies the concentration percentage and
distribution of phosphorus, sulphur, zinc and calcium throughout sample 4.
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Table 3.4
Elemental concentrations in the selected region of Sample 4. Note: percentages do not add
to 100% as lighter elements cannot be detected.

Element
(Name)
Phosphorus (P)
Sulphur (S)
Chlorine (Cl)
Potassium (K)
Calcium (Ca)
Iron (Fe)
Zinc (Zn)
Strontium (Sr)

Atomic No. Concentration
(#)
(%)
15
14.962 ± 2.992
16
3.173 ± 0.635
17
0.105 ± 0.021
19
0.597 ± 0.119
20
30.075 ± 6.015
26
0.056 ± 0.011
30
4.985 ± 0.997
38
0.032 ± 0.006

Figure 3.10 Distribution and concentration percentage of phosphorus, sulphur, zinc and calcium in Sample 4.

3.5

Discussion

From the data obtained from the Heavy Ion Microprobe, it is seen that most of the
samples have a similar formation. Although variations occur in each case, the sam-
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ples display a similar pattern with the high values of calcium, phosphorus and zinc.
The only major discrepancy seen amongst the samples was that of sample 3, in which
a low phosphorus concentration was measured. As the overall concentration percentage is low in this sample, it is likely that this stone may contain a high concentration
of lighter elements not detected by µ-PIXE. Oxides such as carbon carbonate may be
present in the sample accounting for this result.
There are a number of possible discrepancies in the measurement of elemental concentrations which may account for relative variations in the sample results. As the
calcification body is not a flat surface, characteristic x-rays generated from within a
cavity or on the posterior side of the calcification will be attenuated and therefore a
loss of statistical data will occur.
Although relatively unlikely, there is a slight possibility that sample concentrations
may vary due to the synthesis process. If synthesis occurs in a different manner
in each patient, it might explain why relative variations are observed. If time was
permitting, running a number of different stone in each sample may have been useful
to clarify or dispel the findings. With only being able to run four samples, it is
difficult to obtain a total understanding of the concentrations found in a wide variety
of patients. Future examination of multiple samples would be useful to show how
common these finding might be.
As previously mentioned, µ-PIXE is not capable of detecting lighter elements such
as hydrogen, carbon and oxygen which are fundamental components of known calcifications compositions [27], therefore, complete composition analysis is not possible
using this technique alone. PIGE was not available at the facility and therefore this
could not be utilised for the detection of these low Z components. The elemental
concentrations found from these measurements will be of most importance when
applied to simulation studies to understand how varied sample concentrations may
affect LDR brachytherapy treatments.

Chapter 4
Experimental Phantom Studies
4.1

Introduction

This chapter describes the experimental approach that was taken to evaluate the invitro dose perturbations measure by the inclusion of pathological calcification samples (as seen in Chapter 3).
Although in-vivo studies provide the most direct dosimetric measurements, it is often complicated and difficult to obtain such results. Consequently, in-vitro studies
are conducted to provide a more detailed and convenient analysis of the biological
samples of interest. Due to the complex nature of calcifications inside the prostate,
direct dosimetric measurements are impossible to obtain. Therefore, it is possible
to study these formations using samples obtained from patients undergoing radical
prostatectomy. With calculi extracted from the prostatic tissue, dosimetric measurements can be obtained by embedding samples in phantoms and measuring the dose
perturbations caused in the presence of brachytherapy radiation sources. It is possible to measure the absorbed dose in the phantom using a number of dosimeters
strategically placed around the calcification.
In this study, the phantom utilised must be capable of housing calcification samples, interacting closely with LDR brachytherapy sources and allow dosimeters to be
placed in close proximity to the contained samples. To detected any dose reductions
52
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due to the absorption process, it would be favourable to have the brachytherapy seeds
anterior to the calcification sample and the dosimeter sitting posterior to the sample
in order to measure the attenuation dose provided by each sample. This must be
considered for the design of both the phantom and the detector system.

4.2

Materials

4.2.1

Calcifications

4.2.1.1

Pathology Samples

The calcification samples used for the phantom studies are the same as those that
have undergone the µ-PIXE studies conducted in Chapter 3. Although there were
numerous stones in each patient sample set, the aim of this section was to look at a
singular, significant sized (2-3 mm) stone from each patient, and study the dosimetric
effect of these stones alone. It was important to keep the size of the stones used
consistent, as this provides reasonable control in the study. The most significant size
stones were approximately 2-3 mm in diameter, however, due to the rough formation
of these stones, each sample varies to some extent. Individual stone dimensions
selected for phantom insertion are listed in Table 4.1
Table 4.1 Individual stone dimensions selected for phantom insertion

Calcification Sample
Patient 1
Patient 2
Patient 3
Patient 4

Dimensions
(mm)
2.12 × 3.47 × 1.11
1.14 × 1.19 × 0.91*
2.03 × 2.18 × 1.73
2.73 × 2.64 × 1.62

*Patient 2 did not provide any large stones in the sample compared to the other 3
and therefore this was the largest stone available for measurement. Due to the much
smaller dimension of this sample, the attenuation effect of this calcification phantom
is expected to be smaller than the other sample phantoms.
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4.2.1.2

Surrogate Calcifications

Obtaining a large range of patient calcification samples can be a difficult and time
consuming process. Ideally, it would be beneficial if pathological samples could
be roughly approximated by an inexpensive material that does not require surgical
removal or long synthesis techniques. If such material existed, future calcification
studies could be conducted using this surrogate calcification.
As was identified in literature [27], hydroxyapatite (HA) is the most frequent substance that constitutes calcifications, and therefore any potential surrogate must have
a considerable quantity of HA. It was discovered that common calcium rich sources
such as bone, chalk and limestone were not suitable as they lacked the elemental
quantities of the hydroxyapatite formula. Hydroxyapatite powders were also considered, however they were not selected based on the production costs involved. Of
all materials, the highest source of hydroxyapatite was seen in a number of calcium
replacement tablets. The highest of these was Ethical Nutrient’s Bone Builder with
Vitamin D tablets. The contents of individual tablets are given in Table4.2. These
tablets provided much use as they could be simply crushed into a powder or broken
into smaller granules, making their inclusion into phantoms cheap and effective.
Table 4.2 Tablet composition quantities

Contents
Hydroxyapatite
Equiv. Elemental Calcium
Equiv. Elemental Phosphorus
Calcium Hydrogen Phosphate
Equiv. Elemental Calcium
Borax (sodium Borate)
Equivalent elemental Boron
Phytomenadione (Vit. K)
Cholecalciferol (Vit. D3)
Equiv. Cholecalciferol

Quantity
1000mg
225 mg
120 mg
474.5 mg
111.5 mg
8.9 mg
1.0 mg
27 micrograms
8.3 micrograms
333.3 IU
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4.2.2

I-125 Brachytherapy Seeds

The Brachytherapy seeds used for this study are 0.508 U Oncura model 6711 Iodine125 seeds. I-125 seeds are the primary radiation source used for LDR treatments at
St George Cancer Care Clinic. The characteristics of I-125 seeds are given in Table
4.3
Table 4.3 Characteristics of I-125 radionuclide [39]

Decay modes:
Electron capture to first excited state of 125-Te
De-excitation via gamma emission (7%) and internal conversion (93%)
Fluorescent x rays following electron capture and internal conversion
Energy of emitted photons - KeV (number of photons per decay):
27.4 (1.15), 31.4 (0.25), 35.5 (0.067)
Average number of photons per decay: 1.4
Half life: 59.4 days

Radioactive seeds were used in conjunction with individual calcification phantoms
and MOSFET detectors to provide dosimetric data. As previously stated, it is expected that the seed radiation will be perturbed due to the presence of these calcification phantoms. Dosimetric measurements were performed by means of a MOSkinTM detector
(as described in Chapter 2), located behind the calcifications, to measure the effect
of the calcifications on the localised dosimetry. The experimental set-up is shown in
Figure 4.2.

4.2.3

Phantom Material

Polymethyl methacrylate (PMMA) or more commonly known as Perspex is a material which satisfies the requirements of this study. PMMA has been used in a number
of clinical in-vitro studies as it can be fabricated into a wide range of geometries and
varied dimensions. This medium also allows external materials to be placed within
the desired geometry, which for the specific purpose of this study, includes the intro-
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duction of the calcification stones.
Other benefits of PMMA include the relatively low cost and durability of such medium.
PMMA provides substantial protection for the embedded calcifications therefore reducing the possibly of damage to these unique structures between measurements.

4.3

Acrylic Phantom Construction

Figure 4.1 Calibration phantom, tablet phantom (TAB) and four patient phantoms (P1, P2,
P3 & P4)

Flat panel phantoms where chosen as they are capable of sitting very close to the seed
and detector, as well as the ease required to slide panels in and out of the experimental
set up. Each phantom has a dimension of 8 cm by 8 cm by 0.5 cm. A small 0.3 mm
diameter cylindrical well was drilled in the centre of each Perspex sheet which allows
a singular stone to be placed inside the phantom. Each of the 4 patients stones were
encased in their own phantom as well as the powdered tablet surrogate material. Each
phantom is sealed using liquid Perspex and levelled so the panel remains flat with no
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calcification exposure or air gaps. No air was trapped between the calcification and
Perspex seal to maintain homogeneity throughout the different phantoms. A single
Perspex panel with the same dimensions but no calcification inserts was also created
for calibration measurements. The 6 developed phantoms are shown in Figure 4.1.

4.4

Experimental Set-up

The experimental set-up requires the phantom, brachytherapy seed and MOSkinTM to
be surrounded by a homogeneous medium which can be interchanged between measurements. It is also required that the measurements can be reproducible. Due to the
nature of the flat panel phantoms, large, multi-sized, blocks of plastic water created
by Gammex were utilised for the surrounding medium. This medium acts as soft
tissue in which scatter and absorption events can occur. These plastic water blocks
fit tightly and surround the inner phantom, seed and MOSkinTM unit so no air gaps are
apparent. Through this arrangement was easy to interchange the phantoms between
each measurement and replace the surrounding medium while maintaining a fixed
dimension of 30 cm by 30 cm by 30 cm. The experimental configuration for this
series of measurements is shown in Figure 4.2.
In Figure 4.2 the seed, calcification and MOSkinTM were linearly aligned in order to
measure the distal dose through the central region of the calcification. It should also
be noted that the plastic water block above and below the seed and MOSkinTM have a
slight groove which allows the unit to remain flat and maintain homogeneity. Since
the MOSkinTM and seed sit directly onto the surface of the phantom, dose measurements were taken over a total distance of 5 mm. The end of the MOSkinTM was connected to a semiconductor dosimetry system developed by the CMRP which gives
real time readout of the collected charge. Charge collection was taken over a number
of hours (4-9) until sufficient charge collection was obtained (greater than 30 mV).
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Figure 4.2 Phantom, MOSkinTM , I-125 seed and surrounding plastic water unit. Note: although air gaps appear in the figure, the surrounding medium fits tightly together in the
experimental set up, indicated by the arrows.

4.5

Results

The dose rates measured were a direct result of the charge collection rate obtained
from the 6 phantom measurements. Using the measured calibration charge collection rate and the TG-43 dose rate, the calibration factor (V/cGy) was generated and
applied to all further measurements. From individual charge collection rates and the
calibration factor, measured dose rates were obtained for each calcification phantom.
Using TG-43 data and the individual activities of the seeds at time of measurement,
theoretical dose rates through 0.5cm of tissue were obtained to provide the rates that
should be measured without calcification presence. These theoretically measured
dose rates were compared to the experimentally measured dose rates to identify the
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attenuation resulting from each individual calcification body.
Calibration Phantom:
From the calibration measurement, the charge collection rate was recorded as 3.22×10−4
V/min. Using TG-43 data, for a 0.4848 U seed, through 0.5cm of tissue, the dose
rate is given as 1.87cGy/h. From this and the charge rate, the calibration factor was
determined to be 1.03×10−2 V/cGy or 10.3 mV/cGy.

Figure 4.3 Charge collection rate resulting from the calibration phantom.
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Tablet Phantom:
For the tablet embedded phantom, a theoretical dose rate of 1.85 cGy/h was calculated for the 0.4905 U seed. From the charge rate and calibration factor, it was found
that the measured dose rate was 1.84±0.06 cGy/h . This gave a reduced dose rate
of 0.54%, even with such a large volumetric presence, which suggests that the tablet
calcification does not provide the results anticipated from the inclusion of a surrogate calcification, therefore having a negligible impact on the attenuation or this low
energy radiation.

Figure 4.4 Charge collection rate resulting from the tablet phantom.
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Stone 1 Phantom:
The results obtained from the phantom embedded with calcification Stone 1 found a
much larger dose rate reduction. With a theoretical dose rate of 1.78 cGy/h, it was
found that the calcification phantom measured a dose rate of 1.57±0.06 cGy/h. This
gives an 11.8% reduction due to the presence of the calcification sample contained
within the phantom.

Figure 4.5 Charge collection rate resulting from the phantom containing Stone 1.

Experimental Phantom Studies

62

Stone 2 Phantom:
As previously mentioned, the phantom of Stone 2 contains a much smaller sample
than that of the other 3 pathological sample phantoms. This smaller size was an
obvious factor when looking at the measured dose rates of the other calcification
phantoms. Given the theoretical dose rate of 1.76 cGy/h and the measured rate of
1.70±0.06 cGy/h, this body only accounted for a 3.41% reduction to the dose rate.
Although still reasonably important in terms of the dose perturbation, a reduction of
this size is not considered significant in comparison to the other phantom measurements. It should also be noted that the charge collection does not appear to follow
a consistent linear form as well as the other trials and therefore may account for
discrepancies in the measured dose rate.

Figure 4.6 Charge collection rate resulting from the phantom containing Stone 2.
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Stone 3 Phantom:
The phantom of Stone 3 generated a significant reduction to the dose rate, as was
found with stone 1. TG-43 measurements predicted a dose rate of 1.74 cGy/h; however, measurements found that this was reduced to 1.46 cGy/h±0.05 due to the inclusion of this body. When looking at the volumetric properties of the stones selected for
phantom inclusion, stone 3 is slightly smaller than stone 1, however, this calcification
accounts for a reduction of 16% which is 4% greater than stone 1.

Figure 4.7 Charge collection rate resulting from the phantom containing Stone 3.
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Stone 4 Phantom: Of all phantom measurements, Stone 4 provided the most significant impact on the dose rate. Although quite large in volumetric comparisons with
the other samples, this was not excessively large to account for such a big reduction.
With the seed activity 0.4520 U accounting for a theoretical dose rate of 1.72 cGy/h,
it was expected that similar dose rate reductions to that of stone 1 and 3 would be
measured. This however was not the case as the dose rate dropped to 1.03±0.06
cGy/h, causing a reduction of approximately 40%.

Figure 4.8 Charge collection rate resulting from the phantom containing Stone 4.
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Table 4.4
Calcification volumes, theoretical and measured dose rates and the resulting reductions for
each calcification phantom.

Phantom
Tablet
Stone 1
Stone 2
Stone 3
Stone 4

4.6

Calcification
Volume (mm3 )
17.67
8.17
1.23
7.66
11.68

TG-43 Dose
Rate (cGy/h)
1.85
1.78
1.76
1.74
1.72

Measured Dose
Dose Rate
Rate (cGy/h)
Difference (%)
1.84 ± 0.06
-0.54 ± 3.26
1.57 ± 0.06
-11.80 ± 3.82
1.70 ± 0.06
-3.41 ± 3.53
1.46 ± 0.05
-16.09 ± 3.42
1.03 ± 0.06
-40.12 ± 5.83

Discussion

The results obtained from the phantom measurements indicate that there is substantial perturbation to the radiation emitted from the I-125 seed source due to the presence of calcification bodies. Even though only the distal dose was measured, each
pathological calcification, excluding Stone 2, caused a reduction considered clinically important (reductions greater than 6%) as suggested by staff at SGCCC. Stone
2 did cause a reduction to the dose rate by 3%; however with an error limit of 3.5%
this is negligible in the overall results. Given the reduced size of this body, this was
expected and would have been rectified if more stones in the original sample were
available for testing. Looking at stones of comparable volumes (Stone 1 and 3), results indicate there are complimentary findings, suggesting that even though these
two bodies were synthesized in a slightly different fashion as found through chapter
3 µ-PIXE results, reductions were within agreeable limits. The most significant finding through this series of measurements came from the phantom containing Stone 4.
For this large stone, the measured reduction was four times greater than the reduction
caused by Stone 1, and more than double the reduction caused by Stone 3.
If these reductions were prevalent in clinical brachytherapy treatments, prescribed
dose levels may be significantly lowered in specific regions of the prostate. Although
the reductions observed may not account for large impacts on dosimetric parameters
such as D100 , D90 , etc. There would still be an increased chance of under dosage to
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areas containing large, singular calcification formations and even more so, calcification clusters. As the I-125 seeds are within close proximity to the calcification body,
these results can only be applied to similar scenarios in the prostate. Unfortunately,
these studies did not consider the proximal dose measurement or the effect of varied calcification sizes and distributions. This is something that will be significant in
future studies.
One of the purposes of this study was to identify a possible surrogate calcification
which may be used for future calcification studies taking away the need for pathological samples. Even though high in the compositional properties of calcifications
identified in the literature, the surrogate calcium hydroxyapatite tablets selected for
this test did not provide any useful data nor did it agree with the findings of the pathological samples. It is clear from this test that the surrogate calcification chosen for
this study is ineffective and will not serve its intended purpose for future applications.

Chapter 5
Monte Carlo Based Studies
5.1

Introduction

Monte Carlo simulations were used in this study to predict clinical dosimetric quantities that are not easily achieved through physical experimental practices. This study
aims to look at theoretical dose variations that may occur when calcifications are
present in the prostate for patients undergoing LDR brachytherapy treatments. This
study looked at three major physical quantities to analyse the effect of prostatic calculi:
1) The effect of calculi size and position in a set of patient plans using a standard
calcification composition.
2) The effect of changing calculi compositions (as found from ANSTO micro-PIXE
experiment results in Chapter 4) using a single patient plan.
3) The impact of calcifications in the prostate volume on the clinical dosimetric parameters in four patients LDR treatments.
In this project, Geant4 was used to evaluate quantitatively the dosimetric effect of
prostatic calcifications in real clinical treatments. A Geant4 simulation was developed modelling realistic LDR treatments. Number, size and position of calcifications modelled in the simulation are derived from ultrasound LDR treatment images.
67
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Brachytherapy seeds were modelled accurately in terms of geometry, materials and
emitted radiation field; their position in the prostate was derived from real patients’
post implant CT images. The calcifications and brachytherapy seeds were embedded
in a water phantom representing the prostate.
Dose was calculated with and without calcifications in the prostate and the results in
the two alternative cases compared. The Geant4 application is described in detail in
Section 5.2.2.
The simulation application developed in this study is a refinement of the existing
Geant4 application Brachy Plot, developed by the Centre for Medical Radiation
Physics (CMRP). Brachy Plot, described in detail in Section 5.2.2, has been developed specifically for the dosimetric analysis of prostate brachytherapy treatments.

5.2

Methodology

5.2.1

Patient Study Cases

This project aims to study the effect of calcifications in real clinical LDR treatments
conducted at the St. George Cancer Care Centre.
Four patients’ data were made available from the centre and consisted of:

• Ultrasound images with the information of position, number and size of calcification.
• CT images identifying post implant seed insertion points.
5.2.1.1

CT Data

The location of LDR brachytherapy seeds was retrieved from post-implant CT images. The CT data comprises of approximately 12 to 16 transverse images taken
throughout the prostate region in 0.5 cm slices along the scanner axis.
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Figure 5.1 shows an example of a single CT image. The brachytherapy seeds are
visualised as white dots; the seeds contained in the selected slice are highlighted
in green for clarity. The isodose contours visualised in the figure were provided
by the TPS. The process to calculate the position of the brachytherapy seeds is the
following:

• The pixels corresponding to the centre of the brachytherapy seeds contained in
the slice are retrieved.
• The pixel indexes corresponding to the seed location within the prostate is
converted into cm position with respect to the urethra central marker, by means
of a linear conversion equation.

The process of seed position calculation and verification can be found in Appendix
B. This process is repeated for the entire CT data set.

Figure 5.1 Patient CT image with seed identification (green dots).

5.2.1.2

Ultrasound Data

Ultrasound images were used to retrieve the calcification distribution in the patients.
Figure 5.2 shows an example of an ultrasound image representing one 0.5 cm thick
slice along the prostate axis. Slices were acquired to visualise the entire prostate.
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The position and size of the calcifications, outlined by SGCCC staff, were calculated to the nearest pixel, representing the anatomical reference system, depicted in
the figure. This reference grid is in common for all ultrasound images of the same
prostate.
Using ultrasound images to depict calcifications can be hard as in some cases as they
could be confused with streak artefacts.

Figure 5.2 Ultrasound image of a calcification outlined (yellow line) by staff at SGCCC. The
red grid is the reference system to identify location and size of the calcifications. Units are
given in cm.

Due to the complex nature of calcification formations, large single calcifications were
modelled as spheres while clusters were approximated as a group of spheres. This
strategy was adopted as in-house Geant4 studies conducted by the CMRP showed
that calcification stones can be approximated by a number of granular spheres.
The study conducted by Stuart George involved modelling calcifications as clusters
of spherical calcium grains contained in a sphere set at a fixed distance from an I-125
brachytherapy source. The volume of the sphere is kept constant. The dosimetric
effect of the calcification sphere was studied with respect to the size and number of
grains within. This study found that changing the size and number of the granular
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particles inside the spheres, keeping the overall quantity of calcium constant, caused
no difference in the measured dose as seen in Figure 5.3.

Figure 5.3 Point dose at a point 5 mm from a single seed aligned with a granular calcification
as a function of calcification grain size and density. Courtesy of Stuart George.

Adopting the approach mentioned above, in this project calcification clusters imaged
in the ultrasound were approximated by a set of ad-hoc spheres.

5.2.2

Geant4 Brachy Plot Application

The Brachy Plot application has been designed to perform dosimetric studies addressed to clinical LDR brachytherapy treatments.
The user of the application has to define the position and number of I-125 brachytherapy seeds within a 20×20×20 cm water phantom, representing the prostate and the
surrounding soft tissue. The sensitive volume, where the energy deposition is calculated, is a 7×7×7 cm mesh centred within the water phantom.
The Oncura model 6711 I-125 brachytherapy seeds are modelled in the simulation in
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terms of geometry and materials.
The radiation field consists of photons emitted from a random position within the
I-125 core and with random direction. The photons have energy spectrum as shown
in Figure 5.4.

Figure 5.4 Energy spectrum from I-125 brachytherapy seed source.

The physical interactions included in the Geant4 application were modelled by the
Livermore Low Energy Electromagnetic Package [59]. The threshold of production
of secondary particles is fixed to a range of 1 micrometer. The interactions modelled
were photoelectric effect, Compton scattering, Rayleigh scattering for photons and
Bremsstrahlung, ionisation, multiple scattering for electrons. Positrons are not generated in the simulation as the energy of the photons is not high enough to produce
pair production.
Previous brachytherapy simulations conducted by the CMRP using Livermore Low
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Energy Package in the Brachy Plot application have shown agreement with TG43.
The Brachy Plot application produced 100% isodose curves comparable to those
from TG43 standards. On average the 100% isodose curves were within a 1 mm
deviation, with an maximum discrepancy of 4 mm [60].
The energy deposition distribution was calculated in 3D in the sensitive detector, in
0.1×0.1×2 mm voxels. Forty billion events were generated in each brachytherapy
configuration to obtain statistically meaningful results.
The functionality of Brachy Plot was extended for this project to allow for the input
of calcification geometries to study their dosimetric effect.

5.2.3

Extension of Brachy Plot application

A series of modules were added to the Brachy Plot application to model calcifications in the experimental set-up of the simulation. These modules contain the physical properties of calcifications in terms of composition, size and number of calculi
and their position relative to the centre of the phantom. Calculi were modelled by
spheres as explained in detail in Section 5.2.1.2.
Two calcification composition models were adopted to understand the effect of this
parameter on the dosimetric results. The models are:

• Hydroxyapatite composition (Ca10 (PO4 )6 (OH)2 ); this was chosen as it is a reference in the literature [27].
• Composition as measured with ANSTO µ-PIXE (see Chapter 3) in one specific
patient plan. As lighter elements could not be detected by PIXE, it has been
assumed that the missing concentration percentages can be approximated by
oxygen. Although it is expected that hydrogen and carbon would contribute to
the measurements, hydrogen has been neglected as it would be in such small
quantities. Due to relatively close atomic number and mass of oxygen and
carbon, carbon quantities have been approximated by oxygen to avoid compli-
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cation.
Elemental percentages are given for each patient sample in Table 5.1.

Table 5.1 Calcification Simulation Composition Values

Element
(Name)
Phosphorus (P)
Sulphur (S)
Chlorine (Cl)
Potassium (K)
Calcium (Ca)
Iron (Fe)
Zinc (Zn)
Strontium (Sr)
Oxygen (O)

Comp 1
(%)
23.1
1.9×10−1
4.4×10−1
6.2×10−2
39.5
7.0×10−3
7.7
3.5×10−2
28.9

Comp 2
(%)
24.9
3.4×10−1
2.4×10−1
8.3×10−1
35.6
3.0
2.6×10−2
35.1

Comp 3
(%)
1.1
2.7
7.0×10−1
2.6×10−1
27.1
1.2×10−2
4.6×10−1
67.7

Comp 4
(%)
15.0
3.2
1.1×10−1
6.0×10−1
30.1
5.6×10−2
5.0
3.2×10−2
45.9

Figure 5.5 shows an example of simulation experimental set-up. The brachytherapy
seeds are represented in red, the photon tracks are depicted in green, the calcifications
are in blue.
The Geant4 application was used to calculate the dose in the patients deriving from
real LDR sources distribution, with and without the calcifications, with a statistical
uncertainty of 2%. This was achieved using both visual and quantitative analysis.
ROOT [61] was used as an analysis tool. It should be noted that dose is not scored in
the calcification volume or within the I-125 brachytherapy seeds.
The output data generated by Brachy Plot was able to be processed to obtain clinical
parameters D90 , V100 , V150 and V200 . These parameters indicate the effect of the individual patient calcifications over the entire prostate volume and also provide useful
data for the clinical environment.
Each simulation contained a unique data set for a specific patient plan. The brachytherapy seed position and activity was derived from the CT image sets (see Section
5.2.1.1) and simulated accordingly in the Geant4 simulation experimental set-up.
The numbers of brachytherapy seeds varied in the four patient plans: 88, 102, 82 and
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Figure 5.5 Visualisation of the simulation experimental set-up. Brachytherapy seeds (red),
calcifications (blue), photons emitted by I-125 seeds (green).

83. The activities of the seeds were 0.508 U in all cases, except for patient 1 which
was 0.4064 U.
Figure 5.6 shows the 0.5 cm spaced axial planes that identify the z-position of the
prostate in the simulation set up. The placement of I-125 seeds and calcifications
within theses planes correspond to ultrasound and CT image slices. It is important
to note that the axial planes contain the centres of all calcification and brachytherapy
seeds included in the simulation.

Monte Carlo Based Studies

76

Figure 5.6 Schematic of the axial plans within the simulation set up.

5.3

Simulation Results

This section is dedicated to the results obtained by means of the Geant4 application
described in Section 5.2. Subsection 5.3.1 describes the quantitative results found
when varying calculi size and position in a set of patient plans using a standard
hydroxyapatite calcification composition. Section 5.3.2 describes the quantitative
results found from µ-PIXE derived calculi compositions, used in a single patient
plan. Section 5.3.3 describes the results found from the effect of calcifications on the
dosimetric parameters D90 , V100 , V150 and V200 for LDR brachytherapy treatments.

5.3.1

Calcifications with Hydroxyapatite Composition

This section describes the dosimetric of calcifications when an hydroxyapatite composition is adopted. For this section of the study four patient plans were used. These
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plans all varied in seed number, activity, calcification number, distribution and size.
The composition of the calcifications modelled in these simulations were fixed as
hydroxyapatite. The aim of this simulation study was to provide an understanding of
how different sized calcifications affect the dose in a set of real LDR treatments.
In particular, the four patient LDR treatments were studied using hydroxyapatite as
calcification material. To evaluate the effect of the calcifications, the treatment was
simulated with and without calcifications. A subtraction of the energy deposited in
the sensitive volume in the presence of calcifications from the energy deposited without calcifications was performed. This was performed for all voxels of the mesh. As
an example, Figure 5.7 shows the energy deposition in Patient 1 without calcifications, at 1.5 cm along Z axis from the top of the prostate towards the pelvis. The
X-Y coordinates (3 cm, 3 cm) correspond to the centre of the urethra. Figure 5.8
shows the same slice in the presence of calcifications, and Figure 5.9 the difference
between Figure 5.7 and 5.8. Here the black dots represent the brachytherapy seeds,
the white spot is the calcification. The weight of each voxel represents the percentage difference in dose due to the calcification inclusion. As it is shown, there is a
dose reduction around the boundary of the calcification. This analysis procedure was
adopted for all stones, for all patients. A full set of isodose curve plots are given in
Appendix C.
The next subsections are dedicated to the analysis of calcifications for each patient.
The last subsection will be dedicated to the discussion of results obtained here.
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Patient 1 Case

As seen in Figure 5.9, 5.10 and 5.11, Patient 1 displays three z-plane slices (1.5 cm,
2 cm & 2.5 cm) with calcifications present. In the 1.5 cm plane, a singular 1.8 mm
stone is set in the centre of the prostate, sitting to the left of the urethra. This stone
shows a slight dose reduction around the perimeter although the spread is not vast.
This calcification has been identified as Patient 1 Stone 1 in the quantitative results.
The name identifying the calcification has been determined from the identification
number of the stone defined in the ultrasound imaging analysis. The same procedure
is adopted to identify all stones, for all patients.
The second stone identified in the images lies in the 2 cm z-plane. This stone has
a diameter of 2 mm and sits much lower in the prostate volume. In Figure 5.10 it
can be seen that a shadow effect appears to be occurring due to the presence of the
I-125 seed directly to the right of the stone. This was the expected result for such a
scenario. This calcification is referred to as Patient 1 Stone 4.
The final z-plane of interest for Patient 1 is the 2.5 cm plane. In Figure 5.11, a
large singular stone of 3.4 mm diameter is present. This stone appears to be more
centralised as was seen with Stone 1, however, as seen with Stone 4, a shadow effect
is noticed due to the large array of seeds surrounding the posterior of the calcification.
The increased size of this calcification indicates that there is an increased effect on
the reduction of dose surrounding the perimeter. For future reference this body is
referred to as Patient 1 Stone 5.
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Figure 5.7 Isodose curve in patient 1, in 1.5 cm z-plane, without calcification.

Figure 5.8 Isodose curve in patient 1, in 1.5 cm z-plane, with calcification.

Figure 5.9 Comparative dose effect in the 1.5 cm z-plane from calcification presence in
Patient 1. Note: 1 pixel = 0.1 mm.
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Figure 5.10 Comparative dose effect in the 2 cm z-plane from calcification presence in Patient 1. Note: 1 pixel = 0.1 mm.

Figure 5.11 Comparative dose effect in the 2.5 cm z-plane from calcification presence in
Patient 1. Note: 1 pixel = 0.1 mm.
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Figures 5.12, 5.13 and 5.14 show the dose values occurring along the x axis and
through the centre of selected calcifications, in the 1.5, 2 and 2.5 cm z-plane depicted in Figures 5.9, 5.10 and 5.11, respectively, from the edge of the calcification
boundary to the point where the effect of the calcification is negligible. The effect is
negligible when the difference between the dose calculated with and without calcification is smaller than the 4% statistical error affecting the simulations executed with
no calcifications. In the plots the vertical black lines indicate the boundary of the calcification. The black and red dots represent the dose with and without calcification,
respectively. Tables 5.2, 5.3 and 5.4 show a selection of dose values represented in
the Figure 5.12,5.13 and 5.14.
In the plot of Figure 5.12, the 1.8 mm diameter stone shows a reduction on both sides
of the boundary. On the left side there is an initial dose decrease of approximately
11% however this converges within 0.5 mm to the dose without calcification. On the
right side dose reduction is at approximately 16% at the edge and coverges to the
dose calculated wit no calcification within error limits at a distance of 1.2 mm.
Table 5.2 Dose values across the x-plane through the centre of Patient 1 stone 1.

x-Displacement
(mm)
0
0.3
0.5
0.6
2.4
2.5
2.9
3.3
3.7

Dose (Cal)
(Gy)
130.3 ± 2.6
125.1 ± 2.5
118.6 ± 2.4

110.8 ± 2.2
123.0 ± 2.5
124.3 ± 2.5
130.2 ± 2.6

Dose (No Cal)
Difference
(Gy)
(%)
134.1 ± 2.7
-2.8 ± 4.0
130.9 ± 2.6
-4.4 ± 4.0
132.7 ± 2.7
-10.6 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
131.3 ± 2.6
-15.6 ± 4.0
132.9 ± 2.7
-7.4 ± 4.0
131.0 ± 2.6
-5.1 ± 4.0
133.3 ± 2.7
-2.3 ± 4.0
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Figure 5.12 Plot of dose values along the x-plane through the centre (1.8 mm) of Patient 1
stone 1. Note: The black vertical lines indicate the border of the calcification body.

Figure 5.13 shows that the sizable 2 mm stone is located just to the left of a hot
LDR seed. As expected, the greatest site of reduction is on the left of the graph,
as seen in Figure 5.10. Initially the posterior dose shows a very large 25.7% dose
reduction, however, this is reduced to almost 10% within 1mm and then converges
to dose without calcifications at 2.2 mm from the boundary. This shadow effect is
significant. The right side shows a very different behaviour with a small 7% reduction
at the boundary, which then converges to the dose without calcification within 4%
error limit at a 0.4 mm distance from the boundary. This result indicates that a
major region of concern for calcification dose reduction occurs behind stones that
are aligned with LDR brachytherapy seeds. It appears that anterior doses do not
tend to be affected greatly as the seed still delivers very high doses when in close
proximity to the calcification.
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Figure 5.13 Plot of dose values along the x-plane through the centre (2 mm) of Patient 1
stone 4.

Table 5.3 Dose values across the x-plane through the centre of Patient 1 stone 4.

x-Displacement
(mm)
0
0.5
1.0
1.5
2.2
2.3
4.3
4.4
4.6
4.8

Dose (Cal)
(Gy)
181.5 ± 3.6
177.2 ± 3.5
175.5 ± 3.5
172.7 ± 3.5
162.9 ± 3.3

334.9 ± 6.7
370.1 ± 7.4
428.8 ± 8.6

Dose (No Cal)
(Gy)
181.0 ± 3.6
196.8 ± 3.9
196.7 ± 3.9
216.9 ± 4.3
219.3 ± 4.4
Left Calcification Boundary
Right Calcification Boundary
361.3 ± 7.2
386.6 ± 7.7
438.0 ± 8.8

Difference
(%)
0.3 ± 4.0
-10.0 ± 4.0
-10.8 ± 4.0
-20.4 ± 4.0
-25.7 ± 4.0

-7.3 ± 4.0
-4.3 ± 4.0
-2.1 ± 4.0

In Figure 5.14 the 3.4 mm diameter stone shows a dose reduction on either sides of
the boundary although convergence with dose values calculated without calcification
occurs much quicker on the left side of the boundary. Initially the left side has a
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dose reduction of 17.6% at the boundary and becomes negligible at 1.3 mm distance
from the boundary. On the right a higher initial reduction of 23.1% is observed at the
boundary and takes 2.4 mm to become negligible.

Figure 5.14 Plot of dose values along the x-plane through the centre (3.4 mm) of Patient 1
stone 5.

Table 5.4 Dose values across the x-plane through the centre of Patient 1 stone 5.

x-Displacement
(mm)
0
0.7
1.0
1.3
1.4
4.8
4.9
5.5
6.3
7.3

Dose (Cal)
(Gy)
158.8 ± 3.2
148.5 ± 3.0
141.1 ± 2.8
137.8 ± 2.8

114.7 ± 2.3
127.2 ± 2.5
134.0 ± 2.7
140.4 ± 2.8

Dose (No Cal)
(Gy)
164.2 ± 3.3
162.5 ± 3.3
160.5 ± 3.2
167.2 ± 3.3
Left Calcification Boundary
Right Calcification Boundary
149.1 ± 3.0
149.2 ± 3.0
153.1 ± 3.0
144.9 ± 3.0

Difference
(%)
-3.3 ± 4.0
-8.6 ± 4.0
-12.1 ± 4.0
-17.6 ± 4.0

-23.1 ± 4.0
-14.7 ± 4.0
-12.5 ± 4.0
-3.1 ± 4.0
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Patient 2 Case

As seen in Figure 5.15, 5.16 and 5.17, patient 2 displays three z-plane slices (1 cm,
1.5 cm & 2 cm) with calcifications present. In the simulation, thirty three calcifications were modelled, however the small size of a number of stones (<0.5 mm
diameter) show no dosimetric effect. An example of negligible dosimetric effect due
to a small sized calcification can be seen on the 1 cm z-plane in Figure 5.15. This
0.5 mm diameter calcification appears to show practically no impact on dose reduction due to its presence. Although there are some blue spots shown nearby, some of
these may be contributed by statistical variations and not calcification photoelectric
absorption. When this stone was analysed quantitatively, there was no clear indication of a meaningful dose reduction approaching the calcification boundary. As a
result it has been assumed that any individual stone of this size will have a negligible
impact on an LDR brachytherapy treatment and therefore individual calculi smaller
than 0.5mm in diameter will not be evaluated through quantitative analysis. The
negligible impact due to small stones maybe also due to the relative position with
respect to the brachytherapy seeds location. In the case of Patient 2 it was found that
six calcification stones only have a significant dosimetric effect.
The 1.5 cm z-plane in Figure 5.16 shows a unique formation with four stones closely
packed together but not a singular formation. This cluster produces a dose perturbation. The two inner stones are referred to as Patient 2 Stone 27 and 28.
The third plane of interest for patient 2 is the 2 cm z-plane. As seen in Figure 5.17,
two stones are seen both with 1 mm diameter. The positions in which these stones
lie is of great interest due to their proximity to brachytherapy seeds. The first stone
(Patient 2 Stone 32) is the most central stone and is isolated from seed locations. The
second stone (Patient 2 Stone 33) is positioned reasonably close to a seed (approximately 1.5 mm), which would expect a significant dose shadow to be observed on
the basis of the results obtained in the case of Patient 1. Quantitative analysis from
these two stones will be useful for evaluating the positioning effects of calcifications
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and seeds.

Figure 5.15 Comparative dose effect in the 1 cm z-plane from calcification presence in Patient 2. Note: 1 pixel = 0.1 mm.

Figure 5.16 Comparative dose effect in the 1.5 cm z-plane from calcification presence in
Patient 2. Note: 1 pixel = 0.1 mm.
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Figure 5.17 Comparative dose effect in the 2 cm z-plane from calcification presence in Patient 2. Note: 1 pixel = 0.1 mm.

Figures 5.18, 5.19 and 5.20 show the dose values occurring along the x axis and
through the centre of selected calcifications, in the 1.5 and 2 cm z-plane depicted in
Figures 5.16 and 5.17, respectively, from the edge of the calcification boundary to the
point where the effect of the calcification is negligible. The effect is negligible when
the difference between the dose calculated with and without calcification is smaller
than the 4% statistical error affecting the simulations executed with no calcifications.
In the plots the vertical black lines indicate the boundary of the calcification. The
black and red dots represent the dose with and without calcification, respectively.
Tables 5.5, 5.6 and 5.7 show a selection of dose values represented in the Figures
5.18, 5.19 and 5.20.
Figure 5.18 analyses the dose reductions that occur between two inner stones in close
proximity shown in Figure 5.16. Both of 1 mm diameters in size, their combined
affect seems to show the largest boundary reduction found with approximately 61%
on the left and approximately 40% on the right, as shown in the plot. The black lines
in the figure indicate the boundaries of such inner stones. Both these inner stones lie
in the same y-plane and seem to have a more severe impact on the dose distribution in
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comparison to the smaller outer calcifications (see Figure 5.16). The dose reduction
to the calcification is observable up to a maximum distance of approximately 3.5
mm. Between the two inner stones, the dose is reduced between ≈ 44-62% of the
dose without calcifications.

Figure 5.18 Plot of dose values along the x-plane through the centre (both 1 mm) of Patient
2 stone 27 & 28.
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Table 5.5 Dose values across the x-plane through the centre of Patient 2 Stone 27 & 28.

x-Displacement
(mm)
0
0.4
0.8
1.8
2.7
3.3
3.4
4.4
4.5
4.7
4.9
5.1
5.3
5.4
6.4
6.5
7.3
8.4
9.3
10.2

Dose (Cal)
(Gy)
144.1 ± 2.9
142.6 ± 2.9
132.3 ± 2.7
114.1 ± 2.3
101.9 ± 2.0
50.8 ± 1.0

49.1 ± 1.0
73.8 ± 1.5
81.6 ± 1.6
84.6 ± 1.7
70.0 ± 1.4

77.8 ± 1.6
95.8 ± 1.9
105.0 ± 2.1
109.3 ± 2.2
119.1 ± 2.4

Dose (No Cal)
(Gy)
146.9 ± 2.9
155.9 ± 3.1
148.9 ± 3.0
144.2 ± 2.9
138.9 ± 2.8
130.1 ± 2.6
Left Calcification Boundary (27)
Right Calcification Boundary (27)
128.2 ± 2.6
127.5 ± 2.6
127.8 ± 2.6
127.8 ± 2.6
125.9 ± 2.5
Left Calcification Boundary (28)
Right Calcification Boundary (28)
128.6 ± 2.6
128.0 ± 2.6
129.5 ± 2.6
129.5 ± 2.6
128.8 ± 2.6

Difference
(%)
-1.9 ± 4.0
-8.5 ± 4.0
-11.2 ± 4.0
-20.8 ± 4.0
-26.6 ± 4.0
-60.9 ± 4.0

-61.7 ± 4.0
-42.1 ± 4.0
-35.6 ± 4.0
-33.8 ± 4.0
-44.4 ± 4.0

-39.5 ± 4.0
-25.1 ± 4.0
-19.0 ± 4.0
-15.6 ± 4.0
-7.5 ± 4.0

The reduction seen in Figure 5.19 is induced by the isolated 1 mm stone seen in
Figure 5.17. On the left side of the boundary shown in the plot, the dose gradually
converges to the no calcification dose values within 1 mm distance along the x-axis.
On the right side of the boundary, the calcification produces a significant dose reduction up to 1.5 mm distance. Differently from previous analysed cases, the dose
reduction decreases with the distance from the boundary, but it presents some oscillations at approximately 1 mm distance from the calcification. Values of up to 27.7%
of the dose reduction are observed on both boundaries of the calcification along the
x-axis.
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Figure 5.19 Plot of dose values along the x-plane through the centre (1 mm) of Patient 2
stone 32.

Table 5.6 Dose values across the x-plane through the centre of Patient 2 Stone 32.

x-Displacement
(mm)
0
0.4
0.9
1.1
1.2
2.2
2.3
2.7
3.5
4.0

Dose (Cal)
(Gy)
133.2 ± 2.7
128.8 ± 2.6
121.5 ± 2.4
101.7 ± 2.0

103.3 ± 2.1
125.4 ± 2.5
135.2 ± 2.7
141.2 ± 2.8

Dose (No Cal)
(Gy)
137.6 ± 2.8
140.1 ± 2.8
135.2 ± 2.7
140.6 ± 2.8
Left Calcification Boundary
Right Calcification Boundary
143.0 ± 2.9
143.7 ± 2.9
149.1 ± 3.0
143.7 ± 2.9

Difference
(%)
-3.2 ± 4.0
-8.1 ± 4.0
-10.0 ± 4.0
-27.7 ± 4.0

-27.8 ± 4.0
-12.7 ± 4.0
-9.3 ± 4.0
-1.7 ± 4.0

As previously seen in Figure 5.17, Figure 5.20 analyses the stone sitting to the bottom
left of a LDR seed, showing a significant dose reduction. The left side of the plot
displays a tail effect where an initial 27% boundary dose reduction converges to the
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dose calculated with no calcifications within a 2.2 mm distance along the x-axis. On
the right side of the boundary a 25% dose reduction with a very steep gradient is
observed. The calcification dose effect is relevant up to 0.3 mm distance.

Figure 5.20 Plot of dose values along the x-plane through the centre (1 mm) of Patient 2
Stone 33.

Table 5.7 Dose values across the x-plane through the centre of Patient 2 Stone 33.

x-Displacement
(mm)
0
0.6
1.7
2.2
2.3
3.3
3.4
3.5
3.7

Dose (Cal)
(Gy)
139.9 ± 2.8
139.1 ± 2.8
146.3 ± 2.9
129.9 ± 2.6

135.2 ± 2.7
153.3 ± 3.1
168.2 ± 3.4

Dose (No Cal)
(Gy)
143.3 ± 2.9
150.5 ± 3.0
164.0 ± 3.3
178.2 ± 3.6
Left Calcification Boundary
Right Calcification Boundary
179.7 ± 3.6
177.8 ± 3.6
174.3 ± 3.5

Difference
(%)
-2.4 ± 4.0
-7.5 ± 4.0
-10.8 ± 4.0
-27.1 ± 4.0

-24.8 ± 4.0
-13.8 ± 4.0
-3.5 ± 4.0
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Patient 3 case

As seen in Figure 5.21, 5.22 and 5.23, Patient 3 displays three z-plane slices (1.5 cm,
2 cm & 4 cm) with calcifications present. Patient 3 is characterised by five stones
which will be used for quantitative analysis. One peculiar aspect of this case is the
presence of a singular calcification that lies 2 cm away from the other stones in the zplane. In previous patients cases, all calculi a contained within a 1 cm distance along
the z-axis. This patient also displays very large calcifications close to the urethra and
rectum, which are always of concern with brachytherapy treatments.
A calcification is present on the 1.5cm z-plane, with a 1.6 mm diameter. This stone
is referred to as Patient 3 Stone 1. The 2 cm z-plane in Figure 5.22 presents a unique
case with two 3 mm diameter stones close together. These stones are of the largest
size found in any of the patient planes. It is also unique in that both these large
stones appeared to be a singular irregular formation in the CT Data suggesting that
this could be a very rare formation due to its extremely large size. These stones are
identified as Patient 3 Stone 2 and 3 in Figure 5.22. Another important aspect in this
region is the position of one treatment seed lying very closely to the lower right of
the calcification group. Another stone lying on the 2 cm z-plane, referred as Patient
3 Stone 5, has a dosimetric impact.
The final stone analysed for this patient lies on the 4 cm z-plane as seen in Figure
5.23. This stone is identified as Patient 3 Stone 6.
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Figure 5.21 Comparative dose effect in the 1.5 cm z-plane from calcification presence in
Patient 3. Note: 1 pixel = 0.1 mm.

Figure 5.22 Comparative dose effect in the 2 cm z-plane from calcification presence in Patient 3. Note: 1 pixel = 0.1 mm.
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Figure 5.23 Comparative dose effect in the 4 cm z-plane from calcification presence in Patient 3. Note: 1 pixel = 0.1 mm.

Figures 5.24, 5.25, 5.26 and 5.27 show the dose values occurring along the x axis and
through the centre of selected calcifications, in the 1.5, 2 and 4 cm z-plane depicted in
Figures 5.21, 5.22 and 5.23, respectively, from the edge of the calcification boundary
to the point where the effect of the calcification is negligible. The effect is negligible
when the difference between the dose calculated with and without calcification is
smaller than the 4% maximum statistical error affecting the simulations executed
with no calcifications. In the plots the vertical black lines indicate the boundary
of the calcification. The black and red dots represent the dose with and without
calcification, respectively. Tables 5.8, 5.9, 5.10 and 5.11 show a selection of dose
values represented in the Figures 5.24, 5.25, 5.26 and 5.27.
In Figure 5.24, depicting the 1.5 cm z-plane, we can observe a dose reduction at the
boundary of approximately 8% on the left. The dose reduction camn be observed
up to a distance of 1.4 mm. The right side however starts with almost double the
reduction at the boundary (≈ 16%) but only takes 0.4 mm to reach the no calcification
dose values.
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Figure 5.24 Plot of dose values along the x-plane through the centre (1.6 mm) of Patient 3
stone 1.

Table 5.8 Dose values across the x-plane through the centre of Patient 3 Stone 1.

x-Displacement
(mm)
0
0.2
0.4
0.7
1.0
1.4
1.5
3.1
3.2
3.3
3.5
3.6

Dose (Cal)
(Gy)
195.5 ± 3.9
186.2 ± 3.7
184.2 ± 3.7
185.6 ± 3.7
181.6 ± 3.6
182.4 ± 3.7

178.4 ± 3.6
185.0 ± 3.7
195.7 ± 3.9
193.9 ± 3.9

Dose (No Cal)
(Gy)
197.6± 4.0
195.3 ± 3.9
201.7 ± 4.0
209.1 ± 4.2
202.5 ± 4.5
199.0 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
213.2 ± 4.3
212.1 ± 4.2
205.5 ± 4.1
201.0 ± 4.0

Difference
(%)
-1.1± 4.0
-4.6 ± 4.0
-8.7 ± 4.0
-11.2 ± 4.0
-10.3 ± 4.0
-8.3 ± 4.0

-16.3 ± 4.0
-12.8 ± 4.0
-4.8 ± 4.0
-3.5 ± 4.0

The cluster formation of Patient 3 Stone 2 and 3 in Figure 5.22 is similar to that
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seen in the plan of Patient 2 (see Figure 5.16). In 5.22 it can be seen that a single
brachytherapy seed lies to the lower right of the cluster formation, which is significant for LDR seed and calcification positioning analysis. As seen from the dose
plot in Figure 5.25, dose levels on the left side of the plot converge to the case of
no calcifications in the prostate over a distance of 3.6 mm. The initial boundary reduction is 22.14%. The central region between the two inner stone boundaries gives
reductions between 48 and 52%. On the right side of the plot, initial reductions are
just above 4% and converges at a steady rate within 0.8 mm to the dose value without calcifications. It is seen that the anterior region of the calcification is not greatly
affected from the inclusion of this cluster. From this result it can be determined that
the regions receiving the most considerable reductions are those between two stones
and those on the posterior side of a close range brachytherapy source.

Figure 5.25 Plot of dose values along the x-plane through the centre (both 3 mm) of Patient
3 Stone 2 & 3.
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Table 5.9 Dose values across the x-plane through the centre of Patient 3 Stone 2 & 3.

x-Displacement
(mm)
0
1.2
2.7
3.6
3.7
6.7
6.8
7.1
7.2
10.2
10.3
10.7
11.1

Dose (Cal)
(Gy)
204.4 ± 4.1
193.2 ± 3.9
177.0 ± 3.5
160.2 ± 3.2

119.3 ± 2.4
129.9 ± 2.6

836.7 ± 17.3
687.6 ± 13.8
532.8 ± 10.7

Dose (No Cal)
(Gy)
211.0 ± 4.2
210.4 ± 4.2
203.4 ± 4.1
205.7 ± 4.1
Left Calcification Boundary (2)
Right Calcification Boundary (2)
245.2 ± 4.9
251.0 ± 5.0
Left Calcification Boundary (3)
Right Calcification Boundary (3)
875.5 ± 17.5
718.9 ± 14.4
547.6 ± 11.0

Difference
(%)
-3.1 ± 4.0
-8.2 ± 4.0
-13.0 ± 4.0
-22.1 ± 4.0

-51.3 ± 4.0
-48.2 ± 4.0

-4.4 ± 4.0
-4.4 ± 4.0
-2.7 ± 4.0

The isolated stone seen in Figure 5.22 is analysed in the plot in Figure 5.26. This
figure shows a similar reduction on both sides of the plot. The boundary reduction on
the left starts at 17.15% and converges at a distance of 1.6 mm to the dose calculated
with no calcifications. The right side of the plot gives an intial boundary reduction
of 15.5% and converges at a distance of 1.4 mm.
Table 5.10 Dose values across the x-plane through the centre of Patient 3 Stone 5.

x-Displacement
(mm)
0
0.3
1.1
1.6
1.7
3.7
3.8
4.1
4.6
5.2

Dose (Cal)
(Gy)
167.2 ± 3.3
161.2 ± 3.2
154.4 ± 3.1
143.4 ± 2.9

149.6 ± 3.0
164.7 ± 3.3
166.0 ± 3.3
177.6 ± 3.6

Dose (No Cal)
Difference
(Gy)
(%)
169.8 ± 3.5
-1.5 ± 4.0
174.3 ± 3.5
-7.5 ± 4.0
170.7 ± 3.4
-9.5 ± 4.0
173.0 ± 3.5
-17.2 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
177.2 ± 3.5
-15.5 ± 4.0
179.9 ± 3.6
-8.5 ± 4.0
179.8 ± 3.6
-7.7 ± 4.0
182.1 ± 3.6
-2.5 ± 4.0
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Figure 5.26 Plot of dose values along the x-plane through the centre (2 mm) of Patient 3
Stone 5.

In 5.27, the dose reductions occurring either side of the calcification boundary have
a very different behaviour. On the left, a small boundary reduction of 5.5% is found
which then increases before falling back to the dose values of the no calcification
case. The initial dose reduction converges within a distance of 0.5 mm to the dose
calculated with no calcifications. On the right side of the plot, the inital boundary
reduction is 22.9%. The convergence on the right side of the plot occurs over a
distance of 0.8 mm.
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Figure 5.27 Plot of dose values along the x-plane through the centre (1.8 mm) of Patient 3
Stone 6.

Table 5.11 Dose values across the x-plane through the centre of Patient 3 Stone 6.

x-Displacement
(mm)
0
0.2
0.4
0.5
0.6
2.4
2.5
3.0
3.2

Dose (Cal)
(Gy)
154.0 ± 3.1
143.1 ± 2.9
140.4 ± 2.8
143.4 ± 2.9

105.8 ± 2.1
125.3 ± 2.5
130.6 ± 2.6

Dose (No Cal)
Difference
(Gy)
(%)
156.9 ± 3.1
-1.8 ± 4.0
159.0 ± 3.2
-10.0 ± 4.0
153.6 ± 3.1
-8.6 ± 4.0
151.8 ± 3.0
-5.5 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
137.3 ± 2.7
-22.9 ± 4.0
134.4 ± 2.7
-6.8 ± 4.0
134.2 ± 2.7
-2.7 ± 4.0
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Patient 4 case

As seen in Figure 5.28, 5.29, 5.30 and 5.31, Patient 4 displays four z-plane slices
(1.5 cm, 2 cm, 2.5 cm & 3 cm) with calcifications present. Of all patient plans,
Patient 4 contains the most z-planes in which sizeable calcification formations are
observed. Each stone in the set is relatively large and shows a clear indication of
photoelectric absorption occurring around the regions of interest. As has been seen
with all previous patient plans, the 1.5 cm plan once again contains a calcification
body. Figure 5.28 shows a 2.4 mm stone sitting to the lower right of the urethral
position, such a large stone in this region may be beneficial due to dose shadowing
effects. This stone is referred to as Patient 4 Stone 1.
On the 2 cm z-plane (Figure 5.29) a 2 mm stone identified as Patient 4 Stone 4 is
observed.
On the 2.5 cm plane we see 2 stones, both with a 2.2 mm diameter, showing similar
dose perturbations. Due to their isolation and similar position within the plan, it is
not essential to study the effect of both stones and therefore only one has been chosen
for quantitative analysis. The lower of the two was the chosen as it lies closer to the
urethral reference point (0,0) in Figure 5.30. This stone was identified as Patient 4
Stone 7.
The final plane in which calcifications appear is on the 3cm z-plane. In Figure 5.31
we see a four stone cluster in which two stones are 1.3 mm in diameter and slightly
distant from the centre of the prostate, and two stones that are larger (1.8 mm and 1.6
mm diameters) and more central. Only one of the 1.3 mm stones was selected for
further analysis as both showed a relatively similar effect on the surrounding dose
reduction. This stone was chosen to be the higher of the two small stones in Figure
5.31, and was identified as Patient 4 Stone 11. As two previous 1.8 mm diameter
stones were analysed in Patient 1 and 3 (see Figure 5.12 and 5.27), the 1.6 mm stone
was chosen for evaluation. This calcification was identified at Patient 4 Stone 13.
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Figure 5.28 Comparative dose effect in the 1.5 cm z-plane from calcification presence in
Patient 4. Note: 1 pixel = 0.1 mm.

Figure 5.29 Comparative dose effect in the 2 cm z-plane from calcification presence in Patient 4. Note: 1 pixel = 0.1 mm.

Monte Carlo Based Studies

102

Figure 5.30 Comparative dose effect in the 2.5 cm z-plane from calcification presence in
Patient 4. Note: 1 pixel = 0.1 mm.

Figure 5.31 Comparative dose effect in the 3 cm z-plane from calcification presence in Patient 4. Note: 1 pixel = 0.1 mm.

Figures 5.32, 5.33, 5.34, 5.35 and 5.36 show the dose values occurring along the
x axis and through the centre of selected calcifications, in the 1.5, 2, 2.5 and 3 cm
z-plane depicted in Figures 5.28, 5.29, 5.30 and 5.31, respectively, from the edge of
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the calcification boundary to the point where the effect of the calcification is negligible. The effect is negligible when the difference between the dose calculated with
and without calcification is smaller than the 4% statistical error affecting the simulations executed with no calcifications. In the plots the vertical black lines indicate
the boundary of the calcification. The black and red dots represent the dose with
and without calcification, respectively. Tables 5.12, 5.13, 5.14, 5.15 and 5.16 show a
selection of dose values represented in the Figures 5.32, 5.33, 5.34, 5.35 and 5.36.
The plot shown in Figure 5.32 is given for the 2.4 mm isolated stone seen in Figure
5.28. The initial boundary reductions are relatively similar on both sides of the plot
with a 24% reduction on the left and 17% reduction on the right. Although isolated,
it takes a distance of 2.3 mm for convergence with the dose calculated with no calcifications on the left side of the plot, while the right side converges at a distance of 0.6
mm. In previous analysed stones, steep gradients in dose reduction were observed
in the case of calcifications lying close to a brachytherapy seed (see Patient 1 Stone
4 analysed in Figure 5.13). In this case the calcification is not sitting close to a radioactive source in the z-plane, however brachytherapy seeds located in a lower or
higher z-plane slice may contribute to this result.
Table 5.12 Dose values across the x-plane through the centre of Patient 4 stone 1.

x-Displacement
(mm)
0
0.3
0.8
1.4
1.9
2.3
2.4
4.8
4.9
5.2
5.4
5.5

Dose (Cal)
(Gy)
157.0 ± 3.1
152.6 ± 3.1
145.6 ± 2.9
138.6 ± 2.8
131.2 ± 2.6
123.4 ± 2.5

137.8 ± 2.8
142.1 ± 2.8
148.9 ± 3.0
155.5 ± 3.1

Dose (No Cal)
(Gy)
158.7 ± 3.2
161.2 ± 3.2
160.3 ± 3.2
157.0 ± 3.1
157.8 ± 3.2
162.5 ± 3.2
Left Calcification Boundary
Right Calcification Boundary
165.8 ± 3.3
167.3 ± 3.4
165.6 ± 3.3
164.5 ± 3.3

Difference
(%)
-1.1 ± 4.0
-5.4 ± 4.0
-9.1 ± 4.0
-11.7 ± 4.0
-16.9 ± 4.0
-24.2 ± 4.0

-16.9 ± 4.0
-15.1 ± 4.0
-10.1 ± 4.0
-5.5 ± 4.0
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Figure 5.32 Plot of dose values along the x-plane through the centre (2.4 mm) of Patient 4
Stone 1.

Figure 5.33 shows the plot of the 2 mm calcification seen in Figure 5.29. This stone
sits close to the urethra, where a reduced dose is desirable in a clinical treatment.
In Figure 5.33, a significant dose reduction in the area concerning the location of
the urethra is observed (right side of the plot). Initial boundary reductions were
found at only 11% however this reduction converges over a distance of 2.3 mm to the
dose calculated with no calcifications. On the left side of the plot, initial boundary
reduction is slightly higher, at 16%, and becomes negligible at a distance of 1 mm.
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Figure 5.33 Plot of dose values along the x-plane through the centre (2 mm) of Patient 4
Stone 4.

Table 5.13 Dose values across the x-plane through the centre of Patient 4 Stone 4.

x-Displacement
(mm)
0
0.2
0.7
1.0
1.1
3.1
3.2
3.5
4.6
5.1
5.5

Dose (Cal)
(Gy)
160.04 ± 3.2
155.3 ± 3.1
147.8 ± 3.0
143.7 ± 2.9

132.2 ± 2.6
139.8 ± 2.8
145.4 ± 2.9
145.7 ± 2.9
153.3 ± 3.1

Dose (No Cal)
(Gy)
165.4 ± 3.3
167.0 ± 3.4
167.0 ± 3.3
172.2 ± 3.4
Left Calcification Boundary
Right Calcification Boundary
149.9 ± 3.0
157.9 ± 3.2
161.4 ± 3.2
158.1 ± 3.2
158.1 ± 3.2

Difference
(%)
-3.2 ± 4.0
-8.1 ± 4.0
-11.5 ± 4.0
-16.6 ± 4.0

-11.8 ± 4.0
-11.4 ± 4.0
-9.9 ± 4.0
-7.9 ± 4.0
-3.1 ± 4.0

The plot in Figure 5.34 shows the dose statistics across the lower 2.2 mm diameter
calcification in Figure 5.30. In the plot both sides of the calcification experience
a reduction of approximately 17%. On both sides of the plot the dose reduction
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becomes negligible at approximately 2 mm.

Figure 5.34 Plot of dose values along the x-plane through the centre (2.2 mm) of Patient 4
Stone 7.

Table 5.14 Dose values across the x-plane through the centre of Patient 4 Stone 7.

x-Displacement
(mm)
0
0.4
0.9
1.3
1.7
1.8
4.0
4.1
4.8
5.1
5.4
6.0

Dose (Cal)
(Gy)
174.3 ± 3.5
172.5 ± 3.5
165.4 ± 3.3
158.4 ± 3.2
146.9 ± 2.9

145.2 ± 2.9
149.5 ± 3.0
156.8 ± 3.1
157.3 ± 3.2
166.3 ± 3.3

Dose (No Cal)
(Gy)
179.0 ± 3.6
182.2 ± 3.6
179.0 ± 3.6
181.3 ± 3.6
177.7 ± 3.6
Left Calcification Boundary
Right Calcification Boundary
173.9 ± 3.5
171.1 ± 3.4
172.8 ± 3.5
166.1 ± 3.3
172.2 ± 3.4

Difference
(%)
-2.6 ± 4.0
-5.4 ± 4.0
-7.6 ± 4.0
-12.6 ± 4.0
-17.4 ± 4.0

-16.5 ± 4.0
-12.6 ± 4.0
-9.2 ± 4.0
-5.3 ± 4.0
-3.5 ± 4.0
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The plot of Figure 5.35 shows the 1.3 mm diameter stone identified in Figure 5.31.
It can be seen in the plot that a dose gradient is apparent in both cases regardless of
calcification inclusion. On the left side of the boundary the initial reduction is around
8% and takes a distance of 1.7 mm to become negligible. On the right side of the plot
the initial reduction is around 10% but slightly increases to 14% before converging
over a distance of 2.5 mm to the dose value with no calcifications.

Figure 5.35 Plot of dose values along the x-plane through the centre (1.3 mm) of Patient 4
Stone 11.
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Table 5.15 Dose values across the x-plane through the centre of Patient 4 Stone 11.

x-Displacement
(mm)
0
0.3
0.7
1.3
1.7
1.8
3.1
3.2
3.7
4.9
5.3
5.7

Dose (Cal)
(Gy)
203.7 ± 4.1
199.8 ± 4.0
195.9 ± 3.9
186.8 ± 3.7
178.5 ± 3.6

164.1 ± 3.3
166.3 ± 3.3
167.8 ± 3.4
167.2 ± 3.3
167.2 ± 3.3

Dose (No Cal)
Difference
(Gy)
(%)
210.9 ± 4.2
-3.4 ± 4.0
209.1 ± 4.2
-4.5 ± 4.0
204.7 ± 4.1
-4.3 ± 4.0
205.8 ± 4.1
-9.2 ± 4.0
194.8 ± 3.9
-8.4 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
183.3 ± 3.7
-10.4 ± 4.0
181.4 ± 3.6
-8.3 ± 4.0
180.4 ± 3.6
-7.0 ± 4.0
175.4 ± 3.5
-4.7 ± 4.0
173.6 ± 3.5
-3.7 ± 4.0

The plot of the dosimetric effect caused by the 1.6mm stone lying in the lower region
of Figure 5.31 is displayed in Figure 5.36. The left side of the boundary experiences
an 18.6% dose reduction which is reduced to ≈ 8% within 0.1 mm. The dose reduction becomes negligible at a distance of 1 mm. On the right side of the plot, a similar
boundary reduction is seen at 18.3%. The dosimetric results converge to the values
with no calcifications within 1 mm distance from the boundary.
Table 5.16 Dose values across the x-plane through the centre of Patient 4 stone 13.

x-Displacement
(mm)
0
0.2
0.4
0.7
1.0
1.1
2.9
2.8
3.0
3.3
3.6
3.8

Dose (Cal)
(Gy)
190.0 ± 3.8
186.0 ± 3.7
185.4 ± 3.7
183.2 ± 3.7
161.6 ± 3.2

155.0 ± 3.1
165.5 ± 3.3
173.9 ± 3.5
177.9 ± 3.6
183.6 ± 3.7

Dose (No Cal)
Difference
(Gy)
(%)
196.4 ± 3.9
-3.2 ± 4.0
201.5 ± 4.0
-7.7 ± 4.0
199.7 ± 4.0
-7.1 ± 4.0
195.5 ± 3.9
-6.3 ± 4.0
198.5 ± 4.0
-18.6 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
189.7 ± 3.8
-18.3 ± 4.0
192.2 ± 3.8
-13.9 ± 4.0
191.6 ± 3.8
-9.2 ± 4.0
185.3 ± 3.7
-4.0 ± 4.0
185.9 ± 3.7
-1.2 ± 4.0
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Figure 5.36 Plot of dose values along the x-plane through the centre (1.6 mm) of Patient 4
stone 13.

5.3.1.5

Discussion of the Results

In this section, the effect of prostatic calcifications was analysed in real patient’s
LDR treatments, assuming a constant hydroxyapatite calcification composition.
The results show substantial local dose reductions at the boundary of calcifications,
when their diameter is bigger than approximately 0.5 mm. The amount of dose reduction depends strongly on the brachytherapy seeds location and on the size of the
calcification.
Calcification formations with diameter between 1 and 2 mm show dose reductions on
the boundary between 7 and 30%. Calcifications larger than 2 mm in diameter show
dose reductions in a similar range, however, reductions of 20-30% are observed more
often. The most significant dose reductions are found between two large stones in a
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cluster formation (see Figure 5.18 and 5.25) with a reduction of between 33-62%.
Dose reductions are observed up to distances of 0.5 mm-4 mm from the calcification
boundary. These values are strongly dependent on calcification size and proximity to
brachytherapy seeds.
A significant dose reduction (greater than 7%) at the boundary of calcifications with
diameter bigger than 0.5 mm is always observed independently of their relative position with respect to the brachytherapy seeds.
Another significant finding of these simulations is the shadow effect caused by calcification and seed alignment (i.e. Figure 5.13). In this configuration, dose reductions
between 10-30% are observed behind the calcification as in other cases, however the
distance from the calcification boundary where the dose reduction becomes negligible is increased by at least 1 mm.
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Calcifications with µ-PIXE Compositions

Previous section concerned the study of the dosimetric effect of calcifications in relation to their size and distribution. This section is addressed to the study of the
dosimetric effect of different calcification compositions. One patient plan (Patient 3)
was modelled in the Geant4 application using the four calcification compositions obtained from the µ-PIXE results (see Section 5.2.3). The plan of Patient 3 was chosen
as it provided a broad range of calcifications to be analysed.
These results have been analysed by the z-planes in which specific calcification centres lie. This allows comparisons to be drawn between similar stones with varied
composition. In the following Composition 1, 2, 3, 4 identify the calcification composition as illustrated in Section 5.2.3.
1.5 cm z-plane:
The 1.5 cm plane shown in Figure 5.37 identifies the dose reductions caused by the
singular 1.6 mm stone in each varied composition simulation. In the plan of Patient
3 from the previous section (see section 5.3.1) this stone was identified as Stone 1.
Figure 5.37 indicates similar dose reduction occur around the 1.6 mm diameter stone
in each image. When analysing these stones quantitatively, there are noticeable differences in the four plots as shown in Figures 5.38, 5.39, 5.40, and 5.38. Given that
these plots do vary in dose statistics, it is found that on both sides of the calcification
boundary for Stone 1, all four simulations have similar initial boundary reductions
and distance at which calcification dose statistics fall to those without calcifications.
This is seen in Tables 5.17 and 5.18.
Looking at the left side of the plots for the four composition simulations, all initial reductions fall between approximately 9-16% while the distance for statisitics to
converge to the no calcification dose values occur between 1.1-1.4 mm and therefore
only a 0.3 mm variation between all results.
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Figure 5.37 Comparative dose effect in the 1.5 cm z-plane in the four varied calcification
composition simulations, A) Composition 1, B) Composition 2, C) Composition 3, D) Composition 4. Note: 1 pixel = 0.1 mm.

The right side of the calcification boundary shows that the simulation results are
even more consistent between the four simulations. Initial reductions vary between
13-19% and convergence is within 1.1 to 1.3 mm.
The results suggest that compositional variations in the calcification bodies has not
greatly altered the dose reductions experienced between individual cases for this particular stone.
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Table 5.17 boundary reductions and convergence distance on the left of Stone 1.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-13.9 ± 4.0
-16.3 ± 4.0
-9.3 ± 4.0
-11.5 ± 4.0

Convergence distance
(mm)
1.4
1.1
1.1
1.2

Table 5.18 boundary reductions and convergence distance on the right of Stone 1.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-18.7 ± 4.0
-13.0 ± 4.0
-15.3 ± 4.0
-16.1 ± 4.0

Convergence distance
(mm)
1.3
1.2
1.2
1.1
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Figure 5.38 Plot of dose values along the x-plane through the centre of Composition 1 Stone
1.

Table 5.19 Dose values across the x-plane through the centre of Composition 1 Stone 1.

x-Displacement
(mm)
0
0.4
0.8
1.1
1.4
1.5
3.1
3.2
3.6
4.1
4.5

Dose (Cal)
(Gy)
191.2 ± 3.8
188.3 ± 3.8
178.7 ± 3.6
175.9 ± 3.5
171.2 ± 3.4

173.3 ± 3.5
181.4 ± 3.6
195.6 ± 3.9
196.9 ± 3.9

Dose (No Cal)
(Gy)
197.6 ± 4.0
201.7 ± 4.0
209.7 ± 4.2
204.5 ± 4.1
198.9 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
213.2 ± 4.2
200.9 ± 4.0
207.7 ± 4.2
203.9 ± 4.1

Difference
(%)
-3.2 ± 4.0
-6.6 ± 4.0
-14.8 ± 4.0
-14.0 ± 4.0
-13.9 ± 4.0

-18.7 ± 4.0
-9.7 ± 4.0
-5.8 ± 4.0
-3.4 ± 4.0
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Figure 5.39 Plot of dose values along the x-plane through the centre of Composition 2 Stone
1.

Table 5.20 Dose values across the x-plane through the centre of Composition 2 Stone 1.

x-Displacement
(mm)
0
0.3
0.7
1.1
1.2
2.8
2.9
3.3
3.8
4.1

Dose (Cal)
(Gy)
191.2 ± 3.8
188.9 ± 3.8
169.5 ± 3.4
166.4 ± 3.3

185.5 ± 3.7
185.5 ± 3.7
194.5 ± 3.9
202.8 ± 4.1

Dose (No Cal)
Difference
(Gy)
(%)
198.8 ± 4.0
-3.8 ± 4.0
203.3 ± 4.1
-7.1 ± 4.0
202.4 ± 4.0
-16.3 ± 4.0
198.9 ± 4.0
-16.3 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
213.2 ± 4.3
-13.0 ± 4.0
200.9 ± 4.0
-7.7 ± 4.0
207.7 ± 4.2
-6.4 ± 4.0
209.5 ± 4.2
-3.2 ± 4.0
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Figure 5.40 Plot of dose values along the x-plane through the centre of Composition 3 Stone
1.

Table 5.21 Dose values across the x-plane through the centre of Composition 3 Stone 1.

x-Displacement
(mm)
0
0.4
0.7
1.1
1.2
2.8
2.9
3.4
3.9
4.1

Dose (Cal)
(Gy)
198.2 ± 4.0
188.9 ± 3.8
176.1 ± 3.5
180.5 ± 3.6

180.6 ± 3.6
190.4 ± 3.8
191.5 ± 3.8
202.0 ± 4.0

Dose (No Cal)
Difference
(Gy)
(%)
198.8 ± 4.0
-0.3 ± 4.0
203.3 ± 4.1
-7.1 ± 4.0
202.4 ± 4.0
-13.0 ± 4.0
198.9 ± 4.0
-9.3 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
213.2 ± 4.3
-15.3 ± 4.0
208.2 ± 4.2
-8.5 ± 4.0
212.9 ± 4.3
-10.1 ± 4.0
209.5 ± 4.2
-3.6 ± 4.0
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Figure 5.41 Plot of dose values along the x-plane through the centre of Composition 4 Stone
1.

Table 5.22 Dose values across the x-plane through the centre of Composition 4 Stone 1.

x-Displacement
(mm)
0
0.4
0.7
1.2
1.3
2.9
3.0
3.3
3.7
4.1

Dose (Cal)
(Gy)
189.1 ± 3.8
186.6 ± 3.7
188.1 ± 3.8
176.1 ± 3.5

178.9 ± 3.6
188.5 ± 3.8
188.7 ± 3.8
206.3 ± 4.1

Dose (No Cal)
Difference
(Gy)
(%)
195.2 ± 3.9
-3.1 ± 4.0
203.3 ± 4.1
-8.2 ± 4.0
207.3 ± 4.1
-9.3 ± 4.0
198.9 ± 4.0
-11.5 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
213.2 ± 4.2
-16.1 ± 4.0
205.5 ± 4.1
-8.3 ± 4.0
210.6 ± 4.2
-10.4 ± 4.0
213.9 ± 4.3
-3.6 ± 4.0
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2 cm z-plane:
The 2 cm plane in Figure 5.42 shows the dose reductions resulting from the cluster
group composed of two large 3 mm diameter calcifications as seen on the left (identified as Stone 2 and 3 in Patient 3 plan), and the smaller isolated 2 mm stone (Stone
5 in Patient 3 plan) located to the right of the central position. The analysis of these
four simulations will provide two significant results:
1) The effect of compositional changes on a large cluster group sitting in close range
to an LDR brachytherapy seed.
2) The effect of compositional changes on a singular, reasonably isolated 2 mm diameter stone.

Figure 5.42 Comparative dose effect in the 2 cm z-plane in the four varied calcification
composition simulations, A) Composition 1, B) Composition 2, C) Composition 3, D) Composition 4. Note: 1 pixel = 0.1 mm.

When analysing the dose reductions resulting from the cluster group as shown in the
plots of Figures 5.43, 5.44, 5.45 and 5.46, it can be seen that there exists strong similarities between the dose perturbation around this two calcification cluster system.
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In terms of boundary reductions on the left, it can be seen that all compositions fall
within a discrete range (22-26%) as seen in Table 5.23. The distance at which the
calcification statistics converge to those for the case with no calcifications takes no
more than 3.3 mm for all simulations however Composition 2 converges slightly
quicker (2.6 mm) than the other 3 (3.1, 3.3 and 3.1 mm).
In the region that lies between the two calcifications, it can be seen in all cases that the
dose reduction is between 50-60%, as given in Table 5.24. Considering the 4% error
range it appears that the reductions in this region are not greatly affected by changing
composition. The higher oxygen content in Composition 3 (higher concentration of
low Z material) may account for the lower local reduction as this was much smaller
than the other three simulations.
The right side of the calcification boundary indicates similar results are found once
again. Given the position of the brachytherapy seed, very high doses are prescribed
to the anterior boundary of the calcification body however it appears this region is
mildly affected through calcification presence. Looking at Table 5.25, in the case
of Composition 2 and 4, initial reductions are below uncertainty limits immediately.
The initial 5.6% reduction for composition 3 also only takes 0.2 mm to converge. The
only simulation which it appears that dose statistics converge over a large distance is
that of Composition 1, although this is still only 0.8 mm and the initial reduction is
slightly above uncertainty limits at a value of 4.5%.
These results indicate that varied compositions of the calcification cluster appear to
cause similar effects in all cases however the central region between the cluster does
experience a lower reduction in the case of Composition 3.
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Table 5.23 boundary reductions and convergence distance on the left of Stone 2.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-25.8 ± 4.0
-24.0 ± 4.0
-22.4 ± 4.0
-23.6 ± 4.0

Convergence distance
(mm)
3.1
2.6
3.3
3.1

Table 5.24 Average reduction seen in central region between Stone 2 and 3.

Simulation
Average reduction
(#)
(%)
Composition 1
-58.6 ± 4.0
Composition 2
-57.1 ± 4.0
Composition 3
-50.7 ± 4.0
Composition 4
-58.7 ± 4.0

Table 5.25 boundary reductions and convergence distance on the right of Stone 3.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-4.5 ± 4.0
-3.4 ± 4.0
-5.6 ± 4.0
-2.9 ± 4.0

Convergence distance
(mm)
0.8
0
0.2
0
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Figure 5.43 Plot of dose values along the x-plane through the centre of Composition 1 Stone
2 & 3.

Table 5.26
Dose values across the x-plane through the centre of Composition 1 Stone 2 & 3.

x-Displacement
(mm)
0
0.5
1.5
2.5
3.1
3.2
6.2
6.3
6.6
6.7
9.7
9.8
10.1
10.4
10.6

Dose (Cal)
(Gy)
200.1 ± 4.0
186.1 ± 3.7
186.7 ± 3.7
170.4 ± 3.4
152.7 ± 3.1

99.0 ± 2.0
106.8 ± 2.1

835.7 ± 16.7
718.6 ± 14.4
597.6 ± 12.0
528.1 ± 10.6

Dose (No Cal)
(Gy)
205.1 ± 4.1
206.4 ± 4.1
202.7 ± 4.1
203.7 ± 4.1
205.7 ± 4.1
Left Calcification Boundary (2)
Right Calcification Boundary (2)
245.2 ± 4.9
251.0 ± 5.0
Left Calcification Boundary (3)
Right Calcification Boundary (3)
875.5 ± 17.5
763.3 ± 15.3
632.1 ± 12.6
547.6 ± 11.0

Difference
(%)
-2.4 ± 4.0
-9.8 ± 4.0
-7.7 ± 4.0
-16.3 ± 4.0
-25.8 ± 4.0

-59.6 ± 4.0
-57.5 ± 4.0

-4.5 ± 4.0
-5.8 ± 4.0
-5.5 ± 4.0
-3.6 ± 4.0
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Figure 5.44 Plot of dose values along the x-plane through the centre of Composition 2 Stone
2 & 3.

Table 5.27
Dose values across the x-plane through the centre of Composition 2 Stone 2 & 3.

x-Displacement
(mm)
0
0.6
1.3
2.0
2.6
2.7
5.7
5.8
6.1
6.2
9.2
9.3

Dose (Cal)
(Gy)
198.3 ± 4.0
190.8 ± 3.8
170.8 ± 3.4
171.4 ± 3.4
156.4 ± 3.1

104.6 ± 2.1
109.0 ± 2.2

845.7 ± 16.9

Dose (No Cal)
(Gy)
206.4 ± 4.1
207.3 ± 4.1
206.4 ± 4.1
203.7 ± 4.1
205.7 ± 4.1
Left Calcification Boundary (2)
Right Calcification Boundary (2)
245.2 ± 4.9
251.0 ± 5.0
Left Calcification Boundary (3)
Right Calcification Boundary (3)
875.5 ± 17.5

Difference
(%)
-3.9 ± 4.0
-8.0 ± 4.0
-17.2 ± 4.0
-15.9 ± 4.0
-24.0 ± 4.0

-57.5 ± 4.0
56.6 ± 4.0

-3.4 ± 4.0
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Figure 5.45 Plot of dose values along the x-plane through the centre of Composition 3 Stone
2 & 3.

Table 5.28
Dose values across the x-plane through the centre of Composition 3 Stone 2 & 3.

x-Displacement
(mm)
0
0.6
1.5
2.3
3.3
3.4
6.4
6.5
6.8
6.9
9.9
10.0
10.2

Dose (Cal)
(Gy)
205.0 ± 4.1
191.8 ± 3.8
189.5 ± 3.8
169.7 ± 3.4
159.7 ± 3.2

117.9 ± 2.4
126.6 ± 2.5

826.9 ± 16.5
778.3 ± 15.6

Dose (No Cal)
(Gy)
208.2 ± 4.2
210.6 ± 4.2
207.5 ± 4.2
207.0 ± 4.1
205.7 ± 4.1
Left Calcification Boundary (2)
Right Calcification Boundary (2)
245.2 ± 4.9
251.0 ± 5.0
Left Calcification Boundary (3)
Right Calcification Boundary (3)
875.5 ± 17.5
807.6 ± 16.2

Difference
(%)
-1.5 ± 4.0
-8.9 ± 4.0
-8.7 ± 4.0
-18.0 ± 4.0
-22.4 ± 4.0

-51.9 ± 4.0
-49.6 ± 4.0

-5.6 ± 4.0
-3.6 ± 4.0
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Figure 5.46 Plot of dose values along the x-plane through the centre of Composition 4 Stone
2 & 3.

Table 5.29
Dose values across the x-plane through the centre of Composition 4 Stone 2 & 3.

x-Displacement
(mm)
0
0.7
1.6
2.3
3.1
3.2
6.2
6.3
6.6
6.7
9.7
9.8

Dose (Cal)
(Gy)
199.0 ± 4.0
194.9 ± 3.9
179.6 ± 3.5
164.8 ± 3.3
157.1 ± 3.1

98.4 ± 2.0
106.7 ± 2.1

850.5 ± 17.0

Dose (No Cal)
(Gy)
205.1 ± 4.1
210.1 ± 4.2
202.9 ± 4.1
203.6 ± 4.1
205.7 ± 4.1
Left Calcification Boundary (2)
Right Calcification Boundary (2)
245.2 ± 4.9
251.0 ± 5.0
Left Calcification Boundary (3)
Right Calcification Boundary (3)
875.5 ± 17.5

Difference
(%)
-3.0 ± 4.0
-7.2 ± 4.0
-11.5 ± 4.0
-19.1 ± 4.0
-23.6 ± 4.0

-59.5 ± 4.0
-57.5 ± 4.0

-2.9 ± 4.0
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The next stone analysed in the 2 cm plane in the varied composition simulations is
that lying to the upper right of the two stone cluster in Figure 5.42 identified as Stone
5. Analysis of the local reductions through the centre of this stone are presented in
the plots of Figures 5.47, 5.48, 5.49 and 5.50.
From Table 5.30 it can be seen on the left side of the plots, the initial dose reductions
are similar for Composition 1, 2 and 4 with values between 17-22%. Composition
3 appears to be slightly lower at approximately 14%. In Figure 5.49 it can be seen
that this plot also shows a very different presentation to the other three. This distance
at which dose values converge occurs variably over the four simulations. Composition 1 and 2 (the two highest initial reductions) take 1.6 and 1.9 mm respectively
to converge while Composition 3 and 4 both take 1.2 mm. It appears that the initial
reductions has influenced this convergence distance.
The right side of the boundary shows a similar finding as seen in Table 5.31. Similar
initial reductions are found in Composition 1, 2 and 4, while Composition 3 is once
again slightly lower at 11% (3% less than Composition 2). Convergence on the right
side is once again varied between the four simulations however on the right side
of the boundary convergence differs the greatest between Composition 3 and 4 (0.6
mm). On average, convergence on the right takes place over 1 mm.
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Table 5.30 boundary reductions and convergence distance on the left of Stone 5.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-20.9 ± 4.0
-21.9 ± 4.0
-14.0 ± 4.0
-17.3 ± 4.0

Convergence distance
(mm)
1.6
1.9
1.2
1.2

Table 5.31 boundary reductions and convergence distance on the right of Stone 5.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-18.7 ± 4.0
-14.4 ± 4.0
-11.2 ± 4.0
-16.6 ± 4.0

Convergence distance
(mm)
1.0
0.9
0.7
1.3
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Figure 5.47 Plot of dose values along the x-plane through the centre of Composition 1 Stone
5.

Table 5.32 Dose values across the x-plane through the centre of Composition 1 Stone 5.

x-Displacement
(mm)
0
0.4
0.8
1.2
1.6
1.7
3.7
3.8
4.3
4.8

Dose (Cal)
(Gy)
163.3 ± 3.3
159.6 ± 3.2
152.7 ± 3.1
146.4 ± 2.9
136.8 ± 2.7

144.0 ± 2.9
163.3 ± 3.3
178.7 ± 3.6

Dose (No Cal)
(Gy)
169.8 ± 3.4
169.7 ± 3.4
174.3 ± 3.5
175.6 ± 3.5
173.0 ± 3.5
Left Calcification Boundary
Right Calcification Boundary
177.2 ± 3.5
178.6 ± 3.6
184.2 ± 3.7

Difference
(%)
-3.8 ± 4.0
-6.0 ± 4.0
-12.4 ± 4.0
-16.6 ± 4.0
-20.9 ± 4.0

-18.7 ± 4.0
-8.6 ± 4.0
-3.0 ± 4.0
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Figure 5.48 Plot of dose values along the x-plane through the centre of Composition 2 Stone
5.

Table 5.33 Dose values across the x-plane through the centre of Composition 2 Stone 5.

x-Displacement
(mm)
0
0.6
1.3
1.9
2.0
4.0
4.1
4.4
4.7
5.0

Dose (Cal)
(Gy)
172.0 ± 3.4
159.7 ± 3.2
149.4 ± 3.0
135.1 ± 2.7

151.7 ± 3.0
151.7 ± 3.0
158.0 ± 3.1
180.0 ± 3.6

Dose (No Cal)
(Gy)
177.9 ± 3.6
174.3 ± 3.5
170.7 ± 3.4
173.0 ± 3.5
Left Calcification Boundary
Right Calcification Boundary
177.2 ± 3.5
179.7 ± 3.6
180.3 ± 3.6
180.7 ± 3.6

Difference
(%)
-3.3 ± 4.0
-8.4 ± 4.0
-12.5 ± 4.0
-21.9 ± 4.0

-14.4 ± 4.0
-15.6 ± 4.0
-12.4 ± 4.0
-0.4 ± 4.0
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Figure 5.49 Plot of dose values along the x-plane through the centre of Composition 3 Stone
5.

Table 5.34 Dose values across the x-plane through the centre of Composition 3 Stone 5.

x-Displacement
(mm)
0
0.4
0.8
1.2
1.3
3.3
3.4
3.9
4.1

Dose (Cal)
(Gy)
166.0 ± 3.3
157.8 ± 3.2
151.3 ± 3.0
148.7 ± 3.0

157.4 ± 3.1
160.9 ± 3.2
174.5 ± 3.5

Dose (No Cal)
(Gy)
169.7 ± 3.4
174.3 ± 3.5
175.6 ± 3.5
173.0 ± 3.5
Left Calcification Boundary
Right Calcification Boundary
177.2 ± 3.5
178.6 ± 3.6
179.7 ± 3.6

Difference
(%)
-2.2 ± 4.0
-9.5 ± 4.0
-13.8 ± 4.0
-14.0 ± 4.0

-11.2 ± 4.0
-10.1 ± 4.0
-2.9 ± 4.0
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Figure 5.50 Plot of dose values along the x-plane through the centre of Composition 4 Stone
5.

Table 5.35 Dose values across the x-plane through the centre of Composition 4 Stone 5.

x-Displacement
(mm)
0
0.4
0.8
1.2
1.3
3.3
3.4
3.9
4.3
4.7

Dose (Cal)
(Gy)
165.2 ± 3.3
155.3 ± 3.1
148.5 ± 3.0
143.0 ± 2.9

147.8 ± 3.0
166.3 ± 3.3
171.6 ± 3.4
178.6 ± 3.6

Dose (No Cal)
(Gy)
169.7 ± 3.4
174.3 ± 3.5
175.6 ± 3.5
173.0 ± 3.5
Left Calcification Boundary
Right Calcification Boundary
177.2 ± 3.5
178.6 ± 3.6
180.7 ± 3.6
180.9 ± 3.6

Difference
(%)
-2.7 ± 4.0
-10.9 ± 4.0
-15.4 ± 4.0
-17.3 ± 4.0

-16.6 ± 4.0
-6.9 ± 4.0
-5.0 ± 4.0
1.3 ± 4.0
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4 cm z-plane:
The 4 cm plane image output shown in Figure 5.51 identified the isolated 1.8 mm
stone for the four simulation cases. As seen in the figure it appears there is a small
reduction to the right of the stone and appears to be consistent in each case.

Figure 5.51 Comparative dose effect in the 4 cm z-plane in the four varied calcification
composition simulations, A) Composition 1, B) Composition 2, C) Composition 3, D) Composition 4. Note: 1 pixel = 0.1 mm.

The quantitative analysis of the four varied composition simulations is derived from
the plots shown in 5.52, 5.53, 5.54 and 5.55.
The left side of the boundary appears to show the smallest initial reduction upon comparison of the results shown in Tables 5.36 and 5.37. Reductions for Composition
2 and 3 were higher (greater than 10%) than those of the Composition 1 and 4 (less
than 10%). The convergence rate for the left hand side is extremely similar with only
0.2 mm differentiating the smallest and largest case with all values between 0.5-0.7
mm.
On the right hand side of the plots it was found that Composition 1, 2 and 4 varied
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less than 3% and were found in the low to mid 20% range. As found with Stone 1 and
5, Composition 3 was once again lower compared to these other three. In this case
the initial right boundary reduction for Composition 3 was 15.1%. The distance at
which the dose values converged to those of the case without calcifications was also
varied between the four simulations. Compositions 3 converged almost immediately
(0.3 mm), Composition 1 and 4 took 0.7 and 0.6 mm respectively and Composition
2 took 1 mm.
Table 5.36 boundary reductions and convergence distance on the left of Stone 6.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-7.6 ± 4.0
-14.2 ± 4.0
-11.8 ± 4.0
-9.3 ± 4.0

Convergence distance
(mm)
0.7
0.5
0.6
0.5

Table 5.37 boundary reductions and convergence distance on the right of Stone 6.

Simulation
(#)
Composition 1
Composition 2
Composition 3
Composition 4

Initial boundary reduction
(%)
-24.8 ± 4.0
-26.2 ± 4.0
-15.1 ± 4.0
-23.4 ± 4.0

Convergence distance
(mm)
0.7
1.0
0.3
0.6
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Figure 5.52 Plot of dose values along the x-plane through the centre of Composition 1 Stone
6.

Table 5.38 Dose values across the x-plane through the centre of Composition 1 Stone 6.

x-Displacement
(mm)
0
0.2
0.5
0.7
0.8
2.6
2.7
3.1
3.4

Dose (Cal)
(Gy)
152.2 ± 3.0
147.5 ± 3.0
144.1 ± 2.9
140.2 ± 2.8

103.3 ± 2.1
118.2 ± 2.4
129.0 ± 2.6

Dose (No Cal)
Difference
(Gy)
(%)
157.7 ± 3.2
-3.5 ± 4.0
156.9 ± 3.1
-6.0 ± 4.0
155.9 ± 3.1
-7.6 ± 4.0
151.8 ± 3.0
-7.6 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
137.3 ± 2.7
-24.8 ± 4.0
137.6 ± 2.8
-14.1 ± 4.0
134.2 ± 2.7
-3.9 ± 4.0
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Figure 5.53 Plot of dose values along the x-plane through the centre of Composition 2 Stone
6.

Table 5.39 Dose values across the x-plane through the centre of Composition 2 Stone 6.

x-Displacement
(mm)
0
0.3
0.5
0.6
2.4
2.5
2.9
3.2
3.5

Dose (Cal)
(Gy)
156.7 ± 3.1
137.0 ± 2.7
130.3 ± 2.6

101.3 ± 2.0
114.5 ± 2.3
128.4 ± 2.6
129.0 ± 2.6

Dose (No Cal)
(Gy)
156.9 ± 3.1
155.9 ± 3.1
151.8 ± 3.0
Left Calcification Boundary
Right Calcification Boundary
137.3 ± 2.7
137.6 ± 2.8
134.2 ± 2.7
130.8 ± 2.6

Difference
(%)
-0.1 ± 4.0
-12.1 ± 4.0
-14.2 ± 4.0

-26.2 ± 4.0
-16.8 ± 4.0
-4.3 ± 4.0
-1.4 ± 4.0
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Figure 5.54 Plot of dose values along the x-plane through the centre of Composition 3 Stone
6.

Table 5.40 Dose values across the x-plane through the centre of Composition 3 Stone 6.

x-Displacement
(mm)
0
0.4
0.6
0.7
2.5
2.6
2.9

Dose (Cal)
(Gy)
151.3 ± 3.0
141.7 ± 2.8
133.9 ± 2.7

116.5 ± 2.3
131.9 ± 2.6

Dose (No Cal)
Difference
(Gy)
(%)
156.0 ± 3.1
-3.0 ± 4.0
155.9 ± 3.1
-9.1 ± 4.0
151.8 ± 3.0
-11.8 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
137.3 ± 2.7
-15.1 ± 4.0
134.7 ± 2.7
-2.1 ± 4.0
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Figure 5.55 Plot of dose values along the x-plane through the centre of Composition 4 Stone
6.

Table 5.41 Dose values across the x-plane through the centre of Composition 4 Stone 6.

x-Displacement
(mm)
0
0.3
0.5
0.6
2.4
2.5
2.9
3.1

5.3.2.1

Dose (Cal)
(Gy)
153.0 ± 3.1
145.6 ± 2.9
137.7 ± 2.8

105.2 ± 2.1
121.1 ± 2.4
131.6 ± 2.6

Dose (No Cal)
Difference
(Gy)
(%)
156.9 ± 3.1
-2.5 ± 4.0
155.9 ± 3.1
-6.6 ± 4.0
151.8 ± 3.0
-9.3 ± 4.0
Left Calcification Boundary
Right Calcification Boundary
137.3 ± 2.7
-23.4 ± 4.0
137.6 ± 2.8
-12.0 ± 4.0
135.9 ± 2.7
-3.2 ± 4.0

Discussion of the Results

In the previous section, the effect of calcifications with varied compositions in a
single patient plan was studied. The results show similar dosimetric impact, independently from the composition.
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As found in section 5.3.1, this study also showed that the boundary reductions depend strongly on calcification size and proximity to LDR seeds. There was a very
limited dependency of dose reduction with respect to the different calcification compositions. The dose reductions are of the same magnitude of those found with the
fixed hydroxyapatite composition, however slightly larger in most cases. This is determined by the greater presence of high Z elements in the calcification compositions
measured by µ-PIXE.
With respect to Composition 1, 2 and 4, Composition 3 was characterised by smaller
dose reductions in a number of cases, determined by the higher concentration of
oxygen (Z=8) and therefore by a reduced probability of photoelectric absorption.
The results obtained with Composition 3 were closer on average to the results of the
fixed hydroxyapatite composition used on the same patient plan.
In summary, a maximum difference of 11% was found varying the composition of
the calcifications.
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Volumetric Calcification Studies

In this section, the impact of calcifications on the clinical dosimetric parameters for
LDR brachytherapy treatments was studied for the four patients, with a fixed hydroxyapatite calcification composition (see Section 5.3.1). For this study parameters D90 ,
V100 , V150 and V200 were determined based on the simulation results presented in
Section 5.3.1, with and without calcifications. The total surface area and volume for
all calcifications present in the patient plans were calculated and their impact on the
clinical dosimetric parameters for LDR brachytherapy treatments was studied. Most
importantly, this section looks at dosimetric impact on the entire prostate clinical target volume (CTV) which is of concern in clinical treatments, and not just the local
effect as determined in sections 5.3.1 and 5.3.2. This also assumes uniform tumour
development in the target volume.
Since the exact CTV from the treatment plans could not be established in the simulation, and also to eliminate discrepancies directly due to human error during voluming, the 100% isodose surface for the no calcification simulations were taken as
the treatment volume for each simulation. For each study, the treatment volume was
obtained by analysing the dosimetric data from the simulation featuring no calcifications. Any voxel in the simulation data that represented a treatment dose of 144 Gy
or higher was assumed to be within the treatment volume, with the total treatment
volume being the sum of the respective voxels multiplied by the single voxel volume.
To determine the parameter D90 for simulations both with and without calcifications,
the doses within all voxels within the treatment volume were extracted, then sorted
from highest to lowest. The 90th percentile of the collection was specified as D90 .
For each simulation, V100 , V150 and V200 were calculated by summing volume of the
voxels that represented a treatment dose of 144 Gy, 216 Gy and 288 Gy respectively.
5.42 shows the reduction percentage caused to the clinical parameters by the calcification inclusion in the prostatic volume. Complete individual parameter data for all
patient cases can be found in Appendix D.
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Table 5.42
Reduction percentage caused to clinical dosimetric parameters due to calcification inclusion
in four patient plans using a hydroxyapatite composition.

Patient
1
2
3
4
5.3.3.1

Surface
Area (cm2 )
2.56
1.04
3.62
4.30

Volume
(cm3 )
0.23
0.03
0.31
0.27

D90
(%)
-2.83±0.47
-2.39±1.72
-2.36±0.25
-2.27±1.13

V100
(%)
-1.21±0.21
-0.46±0.42
-1.02±0.14
-1.13±0.16

V150
(%)
-1.26±0.33
-0.42±0.21
-2.50±0.10
-1.00±0.32

V200
(%)
-0.51±0.38
-0.12±0.41
-1.02±1.20
-0.51±0.30

Discussion of the Results

The results of Section 5.3.3 showed a reduction of approximately 2% to 3% for D90 ,
independently from the total calcification area and volume. Reductions were also
found in V100 , V150 and V200 although these were much lower with reductions no
greater than 2.5% in all cases. V200 was quite low for all patients and this is likely to
be determined by the distance of calcifications from the brachytherapy seeds. If the
calcifications were closer to the radioactive sources, a more significant reduction of
V200 should be observed.
It was observed that the parameters V100 , V150 and V200 of Patient 2 had reductions
two times smaller than the other three patient cases. This appeared to be determined
by the small total surface area and volume of this patient’s calcifications. Patient 3
is characterised by a higher reduction in V150 and V200 and this should be due to the
presence of a large calcification in very close proximity with a brachytherapy seed
(see section 5.3.1, Figure 5.25).
From the analysis of the dosimetric parameters, the dose reductions calculated in all
patients were not clinically significant as they are smaller than a few percent and
therefore such low reductions over the entire CTV are of little concern in treatment
planning. In regards to the dosimetric parameter D90 , reductions of 2-3% are equivalent to those caused by interseed attenuation effects as studied by Carrier et al. [46].
The details of this study are described in section 2.4.3. As a result of this correlation,
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many clinicians feel that the effects of calcifications are minor.
It is important to note that calcification have a very significant local dosimetric effect
(see Section 5.3.1 and 5.3.2) which is not evaluated in the determination of the dosimetric parameters. This work shows that the use of dosimetric parameters may not
be sufficient to characterise the effect of calcifications.
The study was limited to four patients and it is suggested to extend this work with
more clinical cases, to improve the statistics.

Chapter 6
Conclusion and Future Work
6.1

Conclusion

Brachytherapy is a widely used radiotherapy treatment in Australia and in the world
to cure prostatic cancer. Commercial Treatment Planning Systems (TPSs) approximate all tissues to water without considering the existence of prostatic calcification.
This research consisted in evaluating the dosimetric effect of prostatic calcifications
in real clinical brachytherapy treatments. This work was done in collaboration with
the St. George Cancer Care Centre (SGCCC) and the Australian Nuclear Science
and Technology Organisation (ANSTO).
The morphology of four pathological calcification samples was studied. The size of
a stone can vary from submillimeter size to 3 mm in diameter, the number of stones
in a single patient varied between two to over 80. The shape of the calcifications can
be either spherical or present irregularities. More pathological calcifications should
be studied to increase the statics.
One part of the project consisted in measuring the elemental concentrations in four
pathological calcification samples by means of µ-PIXE analysis, at ANSTO. This
study showed that the higher contributing heavy elements in the calcification composition are calcium, phosphorous, zinc. Oxygen was not detected however this is
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assumed to be one of the most abundant elements as the concentration ratios suggest
a hydroxyapatite composition. From the measurements, the calcification compositions were found to vary significantly among different patients.
Experimental phantom measurements were conducted to quantify the distal dose perturbations caused from the inclusion of four pathological stones. A MOSkinTM detector
was set between a brachytherapy source and the calcification in a PMMA phantom.
Observed dose reductions ranged from 3.41% to 40.12%. A bone builder tablet was
used as calcification surrogate as it is rich in hydroxyapatite, which was indentified
as a calcification composition in the literature. The surrogate did not produce any
significant dose perturbation and proved not to be a suitable model of calcifications
to be used in physical studies.
A Geant4 based brachytherapy TPS verification application was modified to study
the dosimetric effect of calcifications in four real clinical treatments. The position
of the brachytherapy seed and of the calcifications was retrieved by Computed Tomography and ultrasound images. The calcifications were modelled as spheres with
dimensions as determined from patients’ treatment imaging. This study showed that
the presence of calcifications reduce the dose locally. The dose reduction depends
on the size and proximity of the stones to the brachytherapy seeds. The average of
dose reduction at the boundary was approximately 20% and reaching a maximum,
extreme value of 60% at the calcification boundary. On average it was found that
larger stones produce a higher dose reduction at the boundary. On average dose
reductions were observed up to a few millimetres from the calcification boundary,
however severity was dependent strongly on relative location of the stone with respect to the brachytherapy seeds. It was also found that stones with a diameter less
than 0.5 mm cause no local dose perturbation.
Dosimetric parameters used in prostate brachytherapy treatments, D90 , V100 , V150
and V200 , were calculated for the four treatment plans, using a fixed hydroxyapatite
composition. It was found that D90 was reduced consistently between 2-3% regardless of calcification total surface area and volume. The parameters V100 , V150 and
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V200 were affected by calcification surface area and volume, however the effect in
most cases is no more than 1%. Clinically these reductions are considered not significant, however the observed local dose reductions may eventually affect the cancer
treatment clinical outcome. More research in this direction will be of great benefit to
the studies of the effects of prostatic calcifications on the clinical dosimetry of LDR
brachytherapy.
Given the vast differences of calcification formations in individual patient cases, it is
difficult to provide a decisive outcome of this work given the limited data presented.
However from this work, it has been established that high local dose reductions are
a major concern for treatment planning. When presented with a LDR brachytherapy
patient who has large calcification development in the prostate, it may be beneficial
for clinical practitioners to consider the addition of extra I-125 seed near or around
theses formations only if the treatment plan is not compromised.

6.2

Future work

This study has been successful in identifying the dosimetric impact of prostatic calcifications in brachytherapy treatments, however, there are a number of extensions
that can be considered to advance the findings of these results.
Firstly, it would be beneficial to obtain more pathological samples to provide a comprehensive range of calcification formations not only based on their size, but also
their distribution inside the prostate, density properties and compositional structure.
It would also be useful to obtain PIGE measurements to determine the contribution
of elements with an atomic number less than 13. Due to time restraints involved in
the clearance of pathological samples, this was not possible to do for this study.
Since µ-PIXE measurements work most effectively on relatively flat objects, it may
be worthwhile looking at the homogeneity of the calcifications as a whole and trying
to determine if there exists elemental concentration changes throughout the entire
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body i.e. elemental concentration changes in the centre compared to those found on
the surface. Future compositional measurements could also look at determining the
composition of normal prostatic tissue. This would be useful in showing the variation
between prostatic calculi and the surrounding normal tissue.
In regards to phantom measurements, it would be useful to repeat the work done
in this project by using a series of calcifications of varied size i.e. approximately
0.5mm, 1 mm, 2 mm, 3 mm in diameter. It is suggested to repeat the phantom measurements using varied positions of the detector, calcification and brachytherapy seed
in the experimental set up. Multiple seeds could also be utilised in the measurements
to observe the extent of perturbations cause by numerous seeds.
Pathological calcification samples showed that these bodies are not completely spherical in nature and therefore modelling spheres in the simulation with a uniform diameter may affect the dose reductions. For the future it is important to evaluate the
effect of the dose reduction with respect to the shape of the calcification bodies. In
this project, the dose effect of calcifications in the axial planes containing the centre
of the stones was studied. To complete the study, it would be useful to study the effect
of calcifications in 3D. This includes the 3D dose distribution around the entire calcification volume. Other investigations that could be conducted using Monte Carlo
simulations would include determination of reductions to the dosimetric parameters
concerning the organs at risk i.e. the rectum primary parameter D2cc and the urethra
primary parameter D10 .
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Appendix A
µ-PIXE Concentration Maps
A.1

Sample 1

Figure A.1 Sample 1 µ-PIXE Imaging
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µ-PIXE Concentration Maps

A.2

Sample 2

Figure A.2 Sample 2 µ-PIXE Imaging
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µ-PIXE Concentration Maps

A.3

Sample 3

Figure A.3 Sample 3 µ-PIXE Imaging
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µ-PIXE Concentration Maps

A.4

Sample 4

Figure A.4 Sample 4 µ-PIXE Imaging
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Appendix B
Seed Extraction Process
1. Each multi-slice image obtained from SCCC treatment planning software is
saved into a JPEG image file.
2. These images are opened with an image editing program and cropped into an
individual image slice. The Individual slices have the same dimensions as the
CT image software markers are used for the cropping process.
3. The individual images are then opened with image viewing software. Using the
program, pixel values can be measured at each point on the image by moving
the cursor to the desired position.
4. Since the image has an x and y centimetre scale on the axis, a pixels per cm
value can be determined using the program. This is achieved by the line function in which the number of pixels is given per centimetre length.
5. Selecting an image in which the urethra is a predominant structure, the urethra
is established as the central point for the (x, y) position (3 cm, 3 cm). Using
the previously determined pixel per centimetre value and the pixel values for
the urethra, the bottom left corner (0 cm, 0 cm) can be measured. With these
two points a unique calibration equation for both the x and y positions can
be created. This equation takes the input pixel value from image software
measurement and provides an output centimetre value when used in an excel
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spread sheet.
6. The location of each seed is considered as the centre of the large, bright green
spot on the image slice. These green bright spots have been outlined by the
treatment software program in accordance to each patients set up.
7. When each seed pixel value is placed in the excel spreadsheet, the cm x and y
position is given for all seeds in the data set.
8. All seed locations are put into a text file along with the activity of the seeds so
they can be used for visual verification.
Seed text files contain the following information: Seed number, X position (in
cm), Y position (in cm), Z position (in intervals of 0.5 cm, based on the slice
number), Activity (mCi) - this is given on the Ultrasound data.
9. The seed file is run using TG-43 to verify that each seed is in the correct position for each slice. If correct the TG-43 output will look complimentary to
that of the CT slice data which is vital before inclusion into the simulation
application.

Figure B.1 The verification of seed positioning is performed using TG-43 Visual outputs.
This is shown above in which a isodose can be observed for a specified z-plane, the image on
the right shows the positioning of all seeds within plan (green dots) and those seeds which
lie on the plane of interest (red dots).

Appendix C
Isodse Curve Plots for 4 Patient Cases
Using a Hydroxyapatite Calcification
Composition
C.1

Patient 1 Case

C.1.1

1.5 cm z-plane

Figure C.1 Isodose curve in patient 1, in 1.5 cm z-plane, without calcification.
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Figure C.2 Isodose curve in Patient 1, in 1.5 cm z-plane, with calcification.

C.1.2

2 cm z-plane

Figure C.3 Isodose curve in Patient 1, in 2 cm z-plane, without calcification.
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Isodse Curve Plots for 4 Patient Cases Using a Hydroxyapatite Calcification Composition

Figure C.4 Isodose curve in Patient 1, in 2 cm z-plane, with calcification.

C.1.3

2.5 cm z-plane

Figure C.5 Isodose curve in Patient 1, in 2.5 cm z-plane, without calcification.
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Figure C.6 Isodose curve in Patient 1, in 2.5 cm z-plane, with calcification.

C.2

Patient 2 Case

C.2.1

1 cm z-plane

Figure C.7 No Cal isodose line for Patient 2, 1 cm z-plane.
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Figure C.8 Cal isodose line for Patient 2, 1 cm z-plane.

C.2.2

1.5 cm z-plane

Figure C.9 No Cal isodose line for Patient 2, 1.5 cm z-plane.

162

Isodse Curve Plots for 4 Patient Cases Using a Hydroxyapatite Calcification Composition

Figure C.10 Cal isodose line for Patient 2, 1.5 cm z-plane.

C.2.3

2 cm z-plane

Figure C.11 No Cal isodose line for Patient 2, 2 cm z-plane.
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Figure C.12 Cal isodose line for Patient 2, 2 cm z-plane.

C.3

Patient 3 Case

C.3.1

1.5 cm z-plane

Figure C.13 No Cal isodose line for Patient 3, 1.5 cm z-plane.
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Figure C.14 Cal isodose line for Patient 3, 1.5 cm z-plane.

C.3.2

2 cm z-plane

Figure C.15 No Cal isodose line for Patient 3, 2 cm z-plane.
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Figure C.16 Cal isodose line for Patient 3, 2 cm z-plane.

C.3.3

4 cm z-plane

Figure C.17 No Cal isodose line for Patient 3, 4 cm z-plane.
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Figure C.18 Cal isodose line for Patient 3, 4 cm z-plane.

C.4

Patient 4 Case

C.4.1

1.5 cm z-plane

Figure C.19 No Cal isodose line for Patient 4, 1.5 cm z-plane.
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Figure C.20 Cal isodose line for Patient 4, 1.5 cm z-plane.

C.4.2

2 cm z-plane

Figure C.21 No Cal isodose line for Patient 4, 2 cm z-plane.
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Figure C.22 Cal isodose line for Patient 4, 2 cm z-plane.

C.4.3

2.5 cm z-plane

Figure C.23 No Cal isodose line for Patient 4, 2.5 cm z-plane.
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Figure C.24 Cal isodose line for Patient 4, 2.5 cm z-plane.

C.4.4

3 cm z-plane

Figure C.25 No Cal isodose line for Patient 4, 3 cm z-plane.
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Figure C.26 Cal isodose line for Patient 4, 3 cm z-plane.
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Appendix D
Dosimetric Parameter Simulation
Data
D.1

Patient 1

SA: 2.65cm2 , Vol: 0.23cm3
No Calcification
V100 42.1949 cm3
V150 14.0982 cm3
V200 7.02505 cm3
D90 151.381 Gy
Calcification
V100 41.6833 cm3
V150 13.9212 cm3
V200 6.98905 cm3
D90 147.103 Gy
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Dosimetric Parameter Simulation Data

D.2

Patient 2

SA: 1.04cm2 , Vol: 0.03cm3
No Calcification
V100 72.3906 cm3
V150 26.4532 cm3
V200 12.1751 cm3
D90 152.549 Gy
Calcification
V100 72.058 cm3
V150 26.3408 cm3
V200 12.1604 cm3
D90 148.908 Gy

D.3

Patient 3

SA: 3.62cm2 , Vol: 0.31cm3
No Calcification
V100 53.4475 cm3
V150 18.2387 cm3
V200 8.6677 cm3
D90 152.076 Gy
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Dosimetric Parameter Simulation Data

Calcification
V100 52.9016 cm3
V150 17.7833 cm3
V200 8.5795 cm3
D90 148.483 Gy

D.4

Patient 4

SA: 4.30cm2 , Vol: 0.27cm3
No Calcification
V100 53.5699 cm3
V150 21.9637 cm3
V200 10.1719 cm3
D90 154.073 Gy
Calcification
V100 52.9633 cm3
V150 21.7444 cm3
V200 10.1203 cm3
D90 150.582 Gy
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